Drinking Water Health Advisory for Perfluorooctanoic Acid (PFOA)
Drinking Water Health Advisory
for Perfluorooctanoic Acid (PFOA)

Prepared by:

U.S. Environmental Protection Agency
Office of Water (4304T)
Health and Ecological Criteria Division
Washington, DC 20460

EPA Document Number: 822-R-16-005
May 2016
ACKNOWLEDGMENTS

This document was prepared by the Health and Ecological Criteria Division, Office of Science and Technology, Office of Water of the U.S. Environmental Protection Agency (EPA). The Agency gratefully acknowledges the valuable contributions of EPA scientists Glinda Cooper, Ph.D.; Barbara Glenn, Ph.D.; Erin Hines, Ph.D.; Michael Wright, Sc.D.; John Wambaugh, Ph.D.; Thomas Speth, Ph.D.; and Daniel Hautman.

This Health Advisory was provided for review by and comments were received from staff in the following EPA program Offices:

Office of Chemical Safety and Pollution Prevention
Office of Children’s Health Protection
Office of General Counsel
Office of Land and Emergency Response
Office of Policy
Office of Research and Development
Office of Water
# CONTENTS

ACKNOWLEDGMENTS .............................................................................................................. 3

ABBREVIATIONS AND ACRONYMS ....................................................................................... 7

EXECUTIVE SUMMARY ............................................................................................................ 9

1.0 INTRODUCTION AND BACKGROUND ........................................................................ 11
   1.1 Safe Drinking Water Act ................................................................................................. 11
   1.2 Current Advisories and Guidelines ................................................................................. 12
   1.3 Uses of PFOA.................................................................................................................. 14

2.0 NATURE OF THE STRESSOR .......................................................................................... 15
   2.1 Physical and Chemical Properties ................................................................................... 15
   2.2 Occurrence and Sources of Exposure .............................................................................. 17
      2.2.1 Surface Water and Ground Water ............................................................................ 17
      2.2.2 Drinking Water ........................................................................................................ 18
      2.2.3 Food ......................................................................................................................... 18
      2.2.4 Ambient Air ............................................................................................................. 21
      2.2.5 Indoor Dust .............................................................................................................. 22
      2.2.6 Soils.......................................................................................................................... 22
      2.2.7 Biosolids .................................................................................................................. 23
      2.2.8 Consumer Products .................................................................................................. 24
   2.3 Environmental Fate ......................................................................................................... 24
      2.3.1 Mobility.................................................................................................................... 24
      2.3.2 Persistence................................................................................................................ 24
      2.3.3 Bioaccumulation ...................................................................................................... 25
   2.4 Toxicokinetics ................................................................................................................. 25
   2.5 Human Biomonitoring Data ............................................................................................ 27

3.0 PROBLEM FORMULATION ............................................................................................ 28
   3.1 Conceptual Model ........................................................................................................... 28
      3.1.1 Conceptual Model Diagram for Exposure via finished Drinking Water ................. 29
      3.1.2 Factors Considered in the Conceptual Model for PFOA ......................................... 29
   3.2 Analysis Plan ................................................................................................................... 31
      3.2.1 Health Advisory Guidelines ..................................................................................... 31
      3.2.2 Establishing the Data Set ........................................................................................ 31
      3.2.3 Approach for HA Calculation .................................................................................. 32
      3.2.4 Measures of Effect ................................................................................................... 33
      3.2.5 Relative Source Contribution ................................................................................... 34
4.0 EFFECTS ASSESSMENT ............................................................................................................ 35
  4.1 Noncancer Health Effects ..................................................................................................... 35
    4.1.1 Animal Toxicity Studies .......................................................................................... 35
    4.1.2 Human Epidemiology Studies ................................................................................. 39
    4.1.3 Noncancer Mode of Action ...................................................................................... 42
  4.2 Cancer ................................................................................................................................... 44
    4.2.1 Animal Cancer Bioassays ........................................................................................ 44
    4.2.2 Human Epidemiology Studies ................................................................................. 45
    4.2.3 Cancer Mode of Action ............................................................................................ 46
    4.2.4 Weight of Evidence Classification ........................................................................... 47

5.0 DOSE-RESPONSE ASSESSMENT ............................................................................................. 48
  5.1 Uncertainty Factors .............................................................................................................. 50
  5.2 RfD Determination ................................................................................................................ 51

6.0 HEALTH ADVISORY VALUES ................................................................................................. 53
  6.1 Relative Source Contribution .......................................................................................... 53
  6.2 Lifetime Health Advisory ................................................................................................. 54

7.0 QUANTIFICATION OF CANCER RISK ..................................................................................... 56

8.0 EFFECTS CHARACTERIZATION ............................................................................................... 57
  8.1 Uncertainty and Variability ............................................................................................. 57
  8.2 Use of Human Epidemiology Data .................................................................................. 58
  8.3 Consideration of Immunotoxicity .................................................................................... 58
  8.4 Effects on Mammary Gland Development ....................................................................... 60
  8.5 Alternative Exposure Scenarios ....................................................................................... 61
  8.6 Relative Source Contribution Considerations ................................................................... 61
  8.7 Sensitive Populations: Gender Differences ..................................................................... 63
  8.8 Sensitive Populations: Developmental Effects ................................................................. 63

9.0 ANALYTICAL METHODS ......................................................................................................... 64

10.0 TREATMENT TECHNOLOGIES ............................................................................................ 65
11.0 REFERENCES ........................................................................................................................ 69
12.0 APPENDIX A-QUANTITATIVE CANCER ASSESSMENT MODELING ......................... 99
TABLES

Table 1-1. State Guideline Values for PFOA .................................................................13
Table 1-2. International Guideline Values for PFOA.................................................13
Table 2-1. Chemical and Physical Properties of PFOA ..........................................16
Table 5-1. Human Equivalent Doses Derived from the Modeled Animal Average Serum Values .................................................................49
Table 5-2. Candidate RfDs Derived from the HEDs from the Pharmacokinetic Model Average Serum Values .................................................................52

FIGURES

Figure 2-1. Chemical Structures of PFOA and APFO ..............................................15
Figure 3-1. Conceptual Model for PFOA in Finished Drinking Water ................................28
### ABBREVIATIONS AND ACRONYMS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALT</td>
<td>alanine aminotransferase</td>
</tr>
<tr>
<td>ALP</td>
<td>alkaline phosphatase</td>
</tr>
<tr>
<td>APFO</td>
<td>ammonium perfluorooctanoate</td>
</tr>
<tr>
<td>AST</td>
<td>aspartate aminotransferase</td>
</tr>
<tr>
<td>AUC</td>
<td>area under the curve</td>
</tr>
<tr>
<td>BAF</td>
<td>bioaccumulation factor</td>
</tr>
<tr>
<td>BCF</td>
<td>bioconcentration factor</td>
</tr>
<tr>
<td>BMDL</td>
<td>benchmark dose level</td>
</tr>
<tr>
<td>BMF</td>
<td>biomagnification factor</td>
</tr>
<tr>
<td>bw</td>
<td>body weight</td>
</tr>
<tr>
<td>CAR</td>
<td>constitutive androstane receptor</td>
</tr>
<tr>
<td>CCK</td>
<td>cholecystokinin</td>
</tr>
<tr>
<td>CCL</td>
<td>Contaminant Candidate List</td>
</tr>
<tr>
<td>COPD</td>
<td>chronic obstructive airways disease</td>
</tr>
<tr>
<td>CWA</td>
<td>Clean Water Act</td>
</tr>
<tr>
<td>DWEL</td>
<td>drinking water equivalent level</td>
</tr>
<tr>
<td>DWI</td>
<td>drinking water intake</td>
</tr>
<tr>
<td>EPA</td>
<td>U.S. Environmental Protection Agency</td>
</tr>
<tr>
<td>FXR</td>
<td>farnesoid X receptor</td>
</tr>
<tr>
<td>GFR</td>
<td>glomerular filtration rate</td>
</tr>
<tr>
<td>GGT</td>
<td>gamma-glutamyl transferase</td>
</tr>
<tr>
<td>HA</td>
<td>Health Advisory</td>
</tr>
<tr>
<td>HDL</td>
<td>high-density lipoprotein</td>
</tr>
<tr>
<td>HED</td>
<td>human equivalent dose</td>
</tr>
<tr>
<td>HESD</td>
<td>Health Effects Support Document</td>
</tr>
<tr>
<td>IgM</td>
<td>immunoglobulin M</td>
</tr>
<tr>
<td>IRIS</td>
<td>Integrated Risk Information System</td>
</tr>
<tr>
<td>Koc</td>
<td>organic carbon-water partitioning coefficient</td>
</tr>
<tr>
<td>Kow</td>
<td>octanol-water partition coefficient</td>
</tr>
<tr>
<td>LCT</td>
<td>Leydig cell tumor</td>
</tr>
<tr>
<td>LC/MS/MS</td>
<td>liquid chromatography/tandem mass spectrometry</td>
</tr>
<tr>
<td>LDL</td>
<td>low-density lipoprotein</td>
</tr>
<tr>
<td>LOAEL</td>
<td>lowest observed adverse effect level</td>
</tr>
<tr>
<td>MOA</td>
<td>mode of action</td>
</tr>
<tr>
<td>MRL</td>
<td>minimum reporting level</td>
</tr>
<tr>
<td>ng/L</td>
<td>nanograms per liter</td>
</tr>
<tr>
<td>NHANES</td>
<td>National Health and Nutrition Examination Survey</td>
</tr>
<tr>
<td>NOAEL</td>
<td>no observed adverse effect level</td>
</tr>
<tr>
<td>PAC</td>
<td>powdered activated carbon</td>
</tr>
<tr>
<td>PACT</td>
<td>pancreatic acinar cell tumors</td>
</tr>
<tr>
<td>PBPK</td>
<td>physiologically based pharmacokinetic model</td>
</tr>
<tr>
<td>PFAS</td>
<td>perfluoroalkyl substance</td>
</tr>
<tr>
<td>PFC</td>
<td>perfluorinated compounds</td>
</tr>
<tr>
<td>PFOA</td>
<td>perfluorooctanoic acid</td>
</tr>
<tr>
<td>PFOS</td>
<td>perfluorooctanesulfonic acid</td>
</tr>
<tr>
<td>Acronym</td>
<td>Full Form</td>
</tr>
<tr>
<td>---------</td>
<td>-----------</td>
</tr>
<tr>
<td>PTFE</td>
<td>polytetrafluoroethylene</td>
</tr>
<tr>
<td>pg/L</td>
<td>picograms per liter</td>
</tr>
<tr>
<td>PND</td>
<td>post-natal day</td>
</tr>
<tr>
<td>POD</td>
<td>point of departure</td>
</tr>
<tr>
<td>POE</td>
<td>point-of-entry</td>
</tr>
<tr>
<td>POU</td>
<td>point-of-use</td>
</tr>
<tr>
<td>PPARα</td>
<td>peroxisome proliferator activated receptor alpha</td>
</tr>
<tr>
<td>PWS</td>
<td>public water system</td>
</tr>
<tr>
<td>PXR</td>
<td>pregnane X receptor</td>
</tr>
<tr>
<td>REACH</td>
<td>Registration, Evaluation, Authorization, and Restriction of Chemicals</td>
</tr>
<tr>
<td>RfD</td>
<td>reference dose</td>
</tr>
<tr>
<td>RSC</td>
<td>relative source contribution</td>
</tr>
<tr>
<td>SDWA</td>
<td>Safe Drinking Water Act</td>
</tr>
<tr>
<td>SNUR</td>
<td>Significant New Use Rule</td>
</tr>
<tr>
<td>SRBC</td>
<td>sheep red blood cell</td>
</tr>
<tr>
<td>TMF</td>
<td>trophic magnification factor</td>
</tr>
<tr>
<td>TNSSS</td>
<td>Total National Sewage Sludge Survey</td>
</tr>
<tr>
<td>UCMR 3</td>
<td>third Unregulated Contaminant Monitoring Rule</td>
</tr>
<tr>
<td>UF</td>
<td>uncertainty factor</td>
</tr>
<tr>
<td>UV</td>
<td>ultraviolet</td>
</tr>
</tbody>
</table>
EXECUTIVE SUMMARY

Perfluorooctanoic acid (PFOA) is a synthetic, fully fluorinated organic acid; it used in a variety of consumer products and in the production of fluoropolymers, and it is generated as a degradation product of other perfluorinated compounds. Because of strong carbon-fluorine bonds, PFOA is stable to metabolic and environmental degradation. PFOA is one of a large group of perfluoroalkyl substances (PFASs) that are used to make products more resistant to stains, grease, and water. These compounds have been widely found in consumer and industrial products, as well as in food items. Major U.S. manufacturers voluntarily agreed to phase out production of PFOA by the end of 2015. Exposure to PFOA in the United States remains possible due to its legacy uses, existing and legacy uses on imported goods, degradation of precursors, and extremely high persistence in the environment and the human body. PFOA was detected in blood serum in 99% of the U.S. general population between 1999 and 2012; however, the levels of PFOA in blood have been decreasing since U.S. companies began to phase out production. Water resources contaminated by PFOA have been associated with releases from manufacturing sites, industrial sites, fire/crash training areas, and industrial or municipal waste sites where products are disposed of or applied.

The U.S. Environmental Protection Agency (EPA) is issuing a lifetime drinking water Health Advisory (HA) for PFOA of 0.07 micrograms per liter (µg/L) based on a reference dose (RfD) derived from a developmental toxicity study in mice; the critical effects included reduced ossification in proximal phalanges and accelerated puberty in male pups following exposure during gestation and lactation. PFOA is known to be transmitted to the fetus in cord blood and to the newborn in breast milk. This lifetime HA is based on the latest health effects information for noncancer and cancer effects for PFOA as described in EPA’s 2016 Health Effects Support Document for Perfluorooctanoic Acid (PFOA), which was revised following external peer review. Because the developing fetus and newborn are particularly sensitive to PFOA-induced toxicity, the RfD based on developmental effects also is protective of adverse effects in adults (e.g., liver and kidney toxicity). The lifetime HA is therefore protective of the population at large.

For PFOA, oral animal studies of short-term, subchronic, and chronic duration are available in multiple species including monkeys, rats and mice. These studies report developmental effects (survival, body weight changes, reduced ossification, delays in eye opening, altered puberty, and retarded mammary gland development), liver toxicity (hypertrophy, necrosis, and effects on the metabolism and deposition of dietary lipids), kidney toxicity (weight), immune effects, and cancer (liver, testicular, and pancreatic). Overall, the toxicity studies available for PFOA demonstrate that the developing fetus is particularly sensitive to PFOA-induced toxicity. Human epidemiology data report associations between PFOA exposure and high cholesterol, increased liver enzymes, decreased vaccination response, thyroid disorders, pregnancy-induced hypertension and preeclampsia, and cancer (testicular and kidney).

To derive candidate RfDs, EPA used a peer-reviewed pharmacokinetic model to calculate the average serum concentrations associated with candidate no observed adverse effect levels (NOAELs) and lowest observed adverse effect levels (LOAELs) from six studies for multiple effects. Consistent with EPA’s guidance A Review of the Reference Dose and Reference
**Concentration Processes** (USEPA 2002), EPA applied protective uncertainty factors to address intraspecies variability, interspecies variability, and LOAEL to NOAEL extrapolation.

From a national perspective, the dominant source of human exposure to PFOA is expected to be from the diet; indoor dust from carpets and other sources also is an important source of exposure, especially for children. The HA was calculated using a relative source contribution (RSC) of 20%, which allows for other PFOA exposure sources (e.g., dust, diet, air) to make up 80% of the RfD.

EPA’s risk assessment guidelines reflect that, as a general matter, a single exposure to a developmental toxin at a critical time in development can produce an adverse effect (USEPA 1991). In addition, short-term exposure to PFASs can result in a body burden that persists for years and can increase with additional exposures. Thus, EPA recommends that the lifetime HA for PFOA of 0.07 μg/L apply to both short-term (i.e., weeks to months) scenarios during pregnancy and lactation, as well as to lifetime-exposure scenarios.

Adverse effects observed following exposures to PFOA and PFOS are the same or similar and include effects in humans on serum lipids, birth weight, and serum antibodies. Some of the animal studies show common effects on the liver, neonate development, and responses to immunological challenges. Both compounds were also associated with tumors in long-term animal studies. The RfDs for both PFOA and PFOS are based on similar developmental effects and are numerically identical; when these two chemicals co-occur at the same time and location in a drinking water source, a conservative and health-protective approach that EPA recommends would be to compare the sum of the concentrations ([PFOA] + [PFOS]) to the HA (0.07 μg/L).

Under EPA’s *Guidelines for Carcinogen Risk Assessment* (USEPA 2005), there is Suggestive Evidence of Carcinogenic Potential for PFOA. Epidemiology studies demonstrate an association of serum PFOA with kidney and testicular tumors among highly exposed members of the general population. Two chronic bioassays of PFOA support a positive finding for the ability of PFOA to be tumorigenic in one or more organs of rats, including the liver, testes, and pancreas. EPA estimated a cancer slope factor of 0.07 per milligram per kilogram-day (mg/kg-day)$^{-1}$ based on testicular tumors, and confirmed that the lifetime HA based on noncancer effects is protective of the cancer endpoint.
1.0 INTRODUCTION AND BACKGROUND

The U.S. Environmental Protection Agency (EPA) developed the nonregulatory Health Advisory (HA) Program in 1978 to provide information for public health officials or other interested groups on pollutants associated with short-term contamination incidents or spills that can affect drinking water quality, but are not regulated under the Safe Drinking Water Act (SDWA). At present, EPA lists HAs for more than 200 contaminants.¹

HAs identify the concentration of a contaminant in drinking water at which adverse health effects are not anticipated to occur over specific exposure durations (e.g., 1 day, 10 days, a lifetime). HAs serve as informal technical guidance to assist federal, state, and local officials, and managers of public or community water systems in protecting public health when emergency spills or other contamination situations occur. An HA document provides information on the environmental properties, health effects, analytical methodology, and treatment technologies for removing drinking water contaminants.

Perfluorooctanoic acid (PFOA) is a manmade chemical in a large family of chemicals called perfluoroalkyl substances (PFASs) (Buck et al. 2011). PFOA has been used in a variety of consumer products and in the production of fluoropolymers, and is generated as a degradation product of other perfluorinated compounds. PFOA is very persistent in the environment and the human body; it has been detected in water, wildlife, and humans worldwide. This document, EPA’s 2016 Drinking Water Health Advisory for Perfluorooctanoic Acid (PFOA), presents a guideline concentration for PFOA in drinking water at which adverse health effects are not anticipated to occur over a human lifetime. This lifetime HA is based on the latest health effects information for noncancer and cancer effects for PFOA as described in EPA’s Health Effects Support Document for Perfluorooctanoic Acid (PFOA) (USEPA 2016a). The HA value is not a legally enforceable federal standard and is subject to change as new information becomes available. The structure, principles, and approach of this document are consistent with EPA’s Framework for Human Health Risk Assessment to Inform Decision Making (USEPA 2014a).

1.1 Safe Drinking Water Act

SDWA, as amended in 1996, requires EPA to publish a list of unregulated contaminants every 5 years that are not subject to any proposed or promulgated national primary drinking water regulations, are known or anticipated to occur in public water systems (PWSs), and might require regulation under SDWA. This list is known as the Contaminant Candidate List (CCL). PFOA is included on the third CCL (USEPA 2009a) and on the draft fourth CCL (USEPA 2015a).

As part of its responsibilities under SDWA, EPA is required to implement a monitoring program for unregulated contaminants. SDWA requires, among other things, that once every 5 years, EPA issue a list of no more than 30 unregulated contaminants to be monitored by PWSs. In 2012, EPA included PFOA in its third Unregulated Contaminant Monitoring Rule (UCMR 3), which required all large systems serving > 10,000 people, plus a statistically selected group of 800 small systems to monitor for a 1-year period between 2013 and 2015. The last of the

¹ For more information see http://water.epa.gov/drink/standards/hascience.cfm.
monitoring data are still being compiled, but results to-date indicate that PFOA has been measured at or above the minimum reporting level (0.02 micrograms per liter [µg/L]) by approximately 2% of PWSs nationwide. To-date, PFOA has been measured above the new lifetime HA level of 0.07 µg/L by approximately 0.3% of PWSs. Approximately 1% of PWSs have reported data for which combined PFOA and PFOS results are above 0.07 µg/L. For the latest UCMR 3 results, please refer to https://www.epa.gov/dwucmr/occurrence-data-unregulated-contaminant-monitoring-rule#3.

SDWA requires EPA to make regulatory determinations for at least five CCL contaminants every 5 years. EPA must begin developing a national primary drinking water regulation when the Agency makes a determination to regulate based on three criteria:

- The contaminant may have an adverse effect on the health of persons.
- The contaminant is known to occur or there is substantial likelihood the contaminant will occur in public water systems with a frequency and at levels of public health concern.
- In the sole judgment of the Administrator, regulating the contaminant presents a meaningful opportunity for health risk reductions.

To make these determinations, the Agency uses data to analyze occurrence of these compounds in finished drinking water and data on health effects. If EPA determines the contaminant does not meet any one of the three statutory criteria, the Agency’s determination is not to regulate. EPA continues to gather information to inform future regulatory determinations for PFOA under the SDWA.

EPA developed a Health Effects Support Document for Perfluorooctanoic Acid (PFOA) and one for another PFAS, perfluorooctane sulfonate (also known as perfluorooctanesulfonic acid or PFOS), to assist federal, state, tribal and local officials, and managers of drinking water systems in protecting public health when these chemicals are present in drinking water (USEPA 2016a, 2016b). The health effects support documents (HESDs) were peer-reviewed in 2014 and were revised as recommended by the peer reviewers with consideration of public comments and inclusion of additional studies published through December 2015. The revised HESD for PFOA (USEPA 2016a) provides an RfD and cancer assessment that serve as the basis for this HA.

The SDWA provides the authority for EPA to publish nonregulatory HAs or take other appropriate actions for contaminants not subject to any national primary drinking water regulation. EPA is providing this HA for PFOA to assist federal, state, and local officials evaluate risks from this contaminant in drinking water. The HA values consider variability in human response across all life stages and population groups while making allowance for contributions from other exposure media.

1.2 Current Advisories and Guidelines

Currently there are no federal regulations under the SDWA or national recommended ambient water quality criteria under the Clean Water Act (CWA) for PFOA. In January 2009, EPA developed a provisional HA for PFOA in drinking water of 0.4 micrograms per liter (µg/L). The provisional HA was developed to reflect an amount of PFOA that could cause adverse health effects in the short term (weeks to months). The provisional HA was intended as a
guideline for PWSs while allowing time for EPA to develop a lifetime HA. Table 1-1 provides drinking water guideline values that were developed by states.

Table 1-1. State Guideline Values for PFOA

<table>
<thead>
<tr>
<th>State</th>
<th>Guideline Value (µg/ L)</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Delaware Department of Resources and Environmental Control</td>
<td>0.4</td>
<td>DNREC (2016)</td>
</tr>
<tr>
<td>Maine Department of Health and Human Services</td>
<td>0.1</td>
<td>Maine DHHS (2014)</td>
</tr>
<tr>
<td>Michigan Department of Environmental Quality</td>
<td>0.42</td>
<td>Michigan DEQ (2013)</td>
</tr>
<tr>
<td>Minnesota Department of Health</td>
<td>0.3</td>
<td>MDH (2009)</td>
</tr>
<tr>
<td>New Jersey Department of Environmental Protection</td>
<td>0.04</td>
<td>NJDEP (2014)</td>
</tr>
<tr>
<td>North Carolina Division of Water Quality</td>
<td>2</td>
<td>NCDEQ (2013)</td>
</tr>
<tr>
<td>Vermont Agency of Natural Resources</td>
<td>0.02</td>
<td>Vermont ANR (2016)</td>
</tr>
</tbody>
</table>

In 2013 the European Chemicals Agency adopted an agreement that identified PFOA as a “Substance of Very High Concern” because of its persistent, bioaccumulative, and toxic characteristics and placed it onto the Candidate List for Registration, Evaluation, Authorization and Restriction of Chemicals (REACH) (Vierke et al. 2012). Once on the Candidate List, PFOA could be included in Annex XIV of the REACH regulation, which would effectively ban use in manufacturing and in the market.

PFOA also is being considered for listing under The Stockholm Convention on Persistent Organic Pollutants (Convention), a global treaty to protect human health and the environment from persistent organic pollutants. In October 2015, the Persistent Organic Pollutants Review Committee agreed that PFOA meets the screening criteria in Annex D of the Convention, the first of several steps toward listing of chemicals. Listing in various Annexes of the Convention obligates parties to abide by provisions set forth to prohibit, eliminate, or restrict production and use, as well as the import and export of persistent organic pollutants, except as allowed for by specific exemptions. Several international agencies have established guideline values for PFOA (Table 1-2).

Table 1-2. International Guideline Values for PFOA

<table>
<thead>
<tr>
<th>Country/Agency</th>
<th>Guideline Value (µg/ L)</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>German Ministry of Health</td>
<td>0.3</td>
<td>Composite precautionary guidance value for PFOA+PFOS is 0.1</td>
</tr>
</tbody>
</table>
| United Kingdom (UK) Drinking Water Inspectorate | 5.0                     | Action levels:  
Tier 1: potential hazard  
Tier 2: > 0.3  
Tier 3: > 5.0  
Tier 4: > 45 | UK Drinking Water Inspectorate (2009) |
<p>| Danish Ministry of the Environment    | 0.3                     | Composite drinking water criteria are based on relative toxicity of PFOS, PFOA, and PFOSA | Danish Ministry of the Environment (2015) |</p>
<table>
<thead>
<tr>
<th>Country/Agency</th>
<th>Guideline Value (µg/L)</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Swedish National Food Agency</td>
<td>Also 0.09 for the mixture of: PFOS, PFOA, PFHxS; PFBS; PFHpA, PFHsA, PFPeA (total PFASs)</td>
<td>0.9: Pregnant women, women trying to get pregnant, and infants should not consume if total PFASs exceeds</td>
</tr>
</tbody>
</table>

Notes:
PFOA = perfluorooctanoic acid; PFOS = perfluorooctane sulfonate; PFBS = perfluorobutane sulfonate; PFHpA = perfluoroheptanoic acid; PFHsA = perfluorohexanoic acid; PFHxS = perfluorohexane sulfonic acid; PFOSA = perfluorosulfonamide; PFPeA = perfluoropentanoic acid

1.3 Uses of PFOA

Perfluorinated substances, such as PFOA and its derivatives, are water- and lipid-resistant because of their chemical properties. Therefore, they are commonly used as surface-active agents that alter the surface tension of a mixture. Historically, PFOA was used in the United States in carpets, leathers, textiles, upholstering, paper packaging, and coating additives as a waterproofing or stain-resistant agent. Fire resistance of aviation fluid is increased by adding PFOA, PFOS, and other PFASs to the mixture.

In 2006, EPA initiated the 2010/2015 PFOA Stewardship Program in which eight major companies committed to reduce facility emissions and product contents of PFOA and related chemicals on a global basis by 95% no later than 2010, and to work toward eliminating emissions and product content of these chemicals by 2015 (USEPA 2006). Although the 2010/2015 PFOA Stewardship Program has worked toward eliminating emissions and product content, there are still some ongoing uses that EPA is evaluating. Shorter-chain perfluoroalkyl-based products have been developed to replace these chemicals.

To complement the Stewardship Program, EPA developed Significant New Use Rules (SNURs) to allow EPA to review any significant new uses of PFOA and many PFOA-related chemicals before they are commercialized in the United States. On October 22, 2013, EPA issued a final SNUR (published in the Federal Register [FR]; 78 FR 62443) requiring companies to provide notice of any new manufacturing or processing of long-chain perfluoroalkyl carboxylates for use in or on carpets (i.e., to impart soil, water, and stain resistance). Companies must now provide EPA with notice of their intent to manufacture (including import) any of these chemicals if they are used in carpets or to treat carpets. They must also notify EPA for these chemical substances if they intend to import carpets already containing these chemical substances. EPA subsequently proposed another SNUR on January 21, 2015, for PFOA and also for PFOA-related chemicals that have not yet been commercialized (80 FR 2885).

2 For more information on EPA’s SNURs visit http://www.epa.gov/assessing-and-managing-chemicals-under-tsca/long-chain-perfluorinated-chemicals-pfcs.
Given the limited ongoing uses of PFOA-related chemicals, releases to surface water and ground water from PFOA are expected to decline. Exposure to PFOA in the United States remains possible, however, because of its legacy uses, existing and legacy uses on imported goods, degradation of precursors, and extremely high persistence in the environment and in the human body.

2.0 NATURE OF THE STRESSOR

2.1 Physical and Chemical Properties

PFOA and its salts are fluorinated organic compounds and are part of the group of PFASs. PFOA is a completely fluorinated organic synthetic acid that was used in the United States primarily as an aqueous dispersion agent in the manufacture of fluoropolymers and in a variety of water-, oil-, and stain-repellent products. Ammonium perfluorooctanoate (APFO) is the ammonium salt of PFOA (Figure 2-1) which was a processing aid in the manufacture of certain fluoropolymers, especially as an emulsifier during the polymerization of tetrafluoroethylene to make polytetrafluoroethylene (e.g., Teflon™). Most of these primary uses have been voluntarily phased out in the United States as of 2015 (see section 1.3 above); however, limited U.S. uses and imports continue. Some sources of PFOA in the environment result from the atmospheric degradation or transformation and/or surface deposition of precursors, including related fluorinated chemicals (perfluorotelomer alcohols) (Wallington et al. 2006).

![Figure 2-1. Chemical Structures of PFOA and APFO](source: SIAR 2008)

The structure of PFOA varies with the manufacturing process. PFOA can be either a linear or branched eight-carbon carboxylic acid with a partial negative charge on each fluorine and an acidic carboxylate functional group. Low concentrations of other perfluorocarboxylate chain lengths can also be present. It will tend to form micelles in aqueous solution and be attracted to surfaces that are characterized by positive charge.

In the environment, the acidic form ionizes in water to a PFOA anion, and the ammonium salt of PFOA rapidly dissociates. Physical and chemical properties and other reference information for PFOA are provided in Table 2-1. These properties help to define the behavior of PFOA in living systems and the environment. PFOA is a highly stable compound. It is a solid at room temperature with a low vapor pressure. The melting point for PFOA is identified as 50 to 60 degrees Celsius (°C); vapor pressures increase at temperatures near the melting point.
Table 2-1. Chemical and Physical Properties of PFOA

<table>
<thead>
<tr>
<th>Property</th>
<th>Perfluorooctanoic Acid</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemical Abstracts Service</td>
<td>335-67-1</td>
<td>HSDB (2012); Lide (2007); SRC (2016)</td>
</tr>
<tr>
<td>Registry No. (CASRN)⁹</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chemical Abstracts Index Name</td>
<td>2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctanoic acid</td>
<td></td>
</tr>
<tr>
<td>Synonyms</td>
<td>PFOA; Pentadecafluoro-1-octanoic acid; Pentadecafluoro-ν-octanoic acid; Octanoic acid,</td>
<td>Hekster et al. (2003); HSDB (2012); SRC (2016) ATSDR (2015); Kaiser et al. (2005)</td>
</tr>
<tr>
<td></td>
<td>Pentadecafluoro-octanoic acid; Perfluorocaprylic acid; Pentadecafluorooctanoic acid;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Perfluoroheptanecarboxylic acid;</td>
<td></td>
</tr>
<tr>
<td>Chemical Formula</td>
<td>C₈HF₁₅O₂</td>
<td></td>
</tr>
<tr>
<td>Molecular Weight (g/mol)</td>
<td>414.09</td>
<td>HSDB (2012); Lide (2007); SRC (2016)</td>
</tr>
<tr>
<td>Color/Physical State</td>
<td>White powder (ammonia salt)</td>
<td>HSDB (2012); Lewis (2004)</td>
</tr>
<tr>
<td>Boiling Point</td>
<td>192.4 ºC Stable when bound</td>
<td>HSDB (2012); Lide (2007); SRC (2016)</td>
</tr>
<tr>
<td>Melting Point</td>
<td>54.3 ºC Stable when bound</td>
<td>HSDB (2012); Lide (2007); SRC (2016)</td>
</tr>
<tr>
<td>Vapor Pressure</td>
<td>0.525 mm Hg at 25 °C (measured)</td>
<td>Hekster et al. (2003); HSDB (2012); SRC (2016) ATSDR (2015); Kaiser et al. (2005)</td>
</tr>
<tr>
<td></td>
<td>0.962 mm Hg at 59.25 °C (measured)</td>
<td></td>
</tr>
<tr>
<td>Henry’s Law Constant</td>
<td>Not measureable</td>
<td>ATSDR (2015)</td>
</tr>
<tr>
<td>pKa</td>
<td>2.80</td>
<td>SRC (2016)</td>
</tr>
<tr>
<td>K_{oc}</td>
<td>2.06</td>
<td>Higgins and Luthy (2006)</td>
</tr>
<tr>
<td>K_{ow}</td>
<td>Not measurable</td>
<td>ATSDR (2015); EFSA (2008)</td>
</tr>
<tr>
<td>Solubility in Water</td>
<td>9.50 x 10⁶ mg/L at 25 °C (estimated)</td>
<td>ATSDR (2015); Hekster et al. (2003); HSDB (2012); Kauck and Diesslin (1951); SRC (2016)</td>
</tr>
<tr>
<td>Half-life in Air</td>
<td>Stable when bound</td>
<td>UNEP (2015)</td>
</tr>
</tbody>
</table>

Notes:
K_{ow} = octanol-water partition co-efficient; K_{oc} = organic carbon-water partitioning coefficient; g/mol = grams per mole
⁹The CASRN given is for linear PFOA, but the toxicity studies are based on a mixture of linear and branched; thus, the RfD applies to the total linear and branched.

PFOA is a strong acid that is generally present in solution as perfluorooctanoate anion. It is water soluble and mobile in water, with an estimated log K_{oc} of 2.06. PFOA is stable in environmental media because it is resistant to environmental degradation processes, such as biodegradation, photolysis, and hydrolysis. In water, no natural degradation has been demonstrated, and dissipation is by advection, dispersion, and sorption to particulate matter. PFOA has low volatility in ionized form, but can adsorb to particles and be deposited on the ground and into water bodies. Because of its persistence, it can be transported long distances in air or water, as evidenced by detections of PFOA in the arctic media and biota, including in polar bears, ocean-going birds, and fish found in remote areas (Lindstrom et al. 2011a; Smithwick et al. 2006). PFOA is present in ambient air and seawater globally (Ahrens et al. 2011; McMurdo et al. 2008; Yamashita et al. 2005; Young et al. 2007).
2.2 Occurrence and Sources of Exposure

PFOA and other PFASs have been discharged into the environment during use as processing aids for fluoropolymers, by degradation of precursors, including fluorotelomer-based polymers, and throughout the life cycle of products containing these compounds (i.e., from the point of product manufacture through its use and disposal) (Washington et al. 2009, 2015a, 2015b). PFOA and other PFASs are man-made chemicals, but because of their widespread use and chemical and physical properties (persistence and mobility) they have been transported into ground water, surface waters (fresh, estuarine, and marine), and soils in the vicinity of their original source and at great distances. Point sources can result in significant exposure to people in some areas. Major sources of PFOA are described below.

2.2.1 Surface Water and Ground Water

Water resources (i.e., surface water and ground water) are susceptible to contamination by PFOA released from manufacturing sites, industrial use, fire/crash training areas, and industrial or municipal waste sites where products are disposed of or applied. PFOA and other PFASs have been reported in wastewater and biosolids as a result of manufacturing activities, disposal of coated paper and other consumer products, and from washing stain-repellent fabrics (Renner 2009). Historically, land application of biosolids has been a source of PFOA and other PFASs in surface water or ground water (Lindstrom et al. 2011b; Washington et al. 2010a, 2010b). The phase-out of the use of these compounds in the United States is expected to reduce PFASs in biosolids.

Some aqueous film forming foams used to combat aviation (or other hydrocarbon) fires release PFOA to the environment (Seow 2013; USEPA 2014b). Surface and ground water resources in close proximity to airports or other areas where these foams have been used can be contaminated (see Moody et al. 2002). PFOA was reported at concentrations as high as 105 µg/L in ground water near a concrete pad formerly used for military fire-training operations in Michigan (ATSDR 2005; Moody et al. 2003). Surface water concentrations as a result of a release of approximately 22,000 L of AFFF at L.B. Pearson International Airport in Toronto, Canada, resulted in peak PFOA concentrations of 11.3 µg/L at the confluence of Etobicoke Creek and Lake Ontario (Moody et al. 2002).

PFOA is not included as an analyte in the U.S. Geological Survey (USGS) National Water Quality Assessment Program, and it is not monitored in water as part of EPA’s National Aquatic Resource Surveys. PFOA has been reported in U.S. water bodies, including the Tennessee River (<25–598 nanograms per liter [ng/L]), Mississippi River (<1.0–125 ng/L), Lake Erie (21–47 ng/L), Lake Ontario (15–70 ng/L), and the Conasuaga River (253–1,150 ng/L) and Altamaha River (3.0–3.1 ng/L) watersheds in Georgia (Boulanger et al. 2004; Hansen et al. 2002; Konwick et al. 2008; Nakayama et al. 2010). In another study, the USGS collaborated with the University of Maryland and sampled three rivers and streams receiving effluent from 11 wastewater treatment facilities in the Chesapeake Bay watershed (USGS 2011); samples were collected in July and August 2010 from the Potomac River, the Patuxent River, and Saint Mary’s Run. PFOA concentrations ranged from 3.6 to 20 ng/L in the Patuxent River; from 7.5 to 12 ng/L in the Potomac River; and from <2.0 to 47 ng/L in Saint Mary’s Run.
Studies show that PFOA occurs in marine waters. Yamashita et al. (2005) analyzed samples from the Pacific Ocean, South China Sea, and Mid-Atlantic Ocean, as well as samples from coastal waters of several Asian countries. PFOA was found at levels ranging from several thousand picograms per liter (pg/L) in water samples collected from coastal areas in Japan to tens of pg/L in the central Pacific Ocean. Yamashita et al. (2005) reported that PFOA was the predominant PFAS detected in oceanic waters, followed by PFOS.

### 2.2.2 Drinking Water

Under EPA’s UCMR 3, PFOA was monitored by approximately 5,000 PWSs (all PWSs serving > 10,000 people, and a representative sample of 800 small PWSs) from 2013 through December 2015. The minimum reporting level (MRL) for PFOA in this survey was 0.02 μg/L. To-date, results for more than 36,000 samples have been reported by more than 4,800 PWSs for PFOA. The remainder of the results are expected to be reported by mid-2016. PFOA was measured at or above the MRL by approximately 2% of the PWSs. PFOA was reported above 0.07 μg/L by approximately 0.3% of PWSs that have reported results. Approximately 1% of PWSs have reported data for which combined PFOA and PFOS results are above 0.07 μg/L.

The Environmental Working Group’s (EWG)

The Environmental Working Group’s (EWG[^3]) National Drinking Water Database includes PFOA analysis at 24 systems between 2004 and 2009 (EWG 2015). EWG obtained data primarily from state drinking water offices; the database includes data from 47,677 water systems in 45 states and the District of Columbia. The database showed that 24 systems reported analyzing for PFOA; of these, five systems in Minnesota reported finding detectable levels. Four of the systems had average concentrations below 0.01 μg/L. One system had an average concentration of 0.09 μg/L and a maximum reported concentration of 0.25 μg/L.

PFOA detections in source water and drinking water are reported in several published studies. These studies frequently involve targeted local sampling; thus, the findings are not representative of national occurrence. For example, in New Jersey, monitoring of raw and finished water between 2006 and 2008 revealed concentrations as high as 0.14 μg/L in finished drinking water (NJDEP 2007; Post et al. 2009). In another study, PFOA concentrations in Little Hocking, Ohio, ranged from 1.5 and 7.2 μg/L in the municipal water distribution system and up to 14 μg/L in private wells between 2002 and 2005 (Emmett et al. 2006). A study in Minnesota reported PFOA concentrations up to 0.9 μg/L in municipal, noncommunity, and private wells between 2004 and 2008 (Goeden and Kelly 2006).

### 2.2.3 Food

PFOA ingestion from food is an important exposure source. PFOA was detected in a variety of food products including snack foods, vegetables, meat, dairy products, human breast milk, and fish, using data from Europe and North America as reported by Trudel et al. (2008). In North America, snack foods, fish and shellfish, and potatoes were the food items estimated to contribute the most to PFOA exposure, under intermediate and high-exposure conditions. In a survey that included multiple food types, PFOA was the second-most frequently detected PFAS.

[^3]: For more information see [http://www.ewg.org](http://www.ewg.org).
and was present at high concentrations relative to other related compounds (Hlouskova et al. 2013). In a 2011 assessment of exposure to Americans, Lorber and Egeghy (2011) concluded that food ingestion appears to be the primary route of exposure in adults, and dust and dietary ingestion is the major contributor for young children, under typical exposure conditions. Recent evidence shows that PFOA levels in food have been declining (Johansson et al. 2014).

Schecter et al. (2010) collected 10 samples of 31 commonly consumed foods from five grocery stores in Dallas, Texas, in 2008 and analyzed them for PFOA. Equal weights of each sample were combined and composited for analysis. Dietary intakes were estimated using data from the 2007 U.S. Department of Agriculture food availability data set. For concentrations below the limit of detection, a value of zero was assigned. The estimated per capita daily estimate for exposure to PFOA was 60 nanograms per day (ng/day), or about 0.75 ng/day for an 80 kilogram (kg) adult. Based on a graphic presentation in the published paper, meat products (n = 8) accounted for about 40 ng/day with the remaining 30% equally distributed between fish (n = 7), vegetables (n = 7: three fat [olive oil, canola, margarine], one cereal, one apple, one potato, and one peanut butter sample), and dairy and egg products (n = 9).

Tittlemier et al. (2007) conducted a Canadian total diet study that collected and analyzed 54 composite food samples. Samples were collected from 1992 to 2004 and represented fish and seafood, meat, poultry, frozen entrées, fast food, and microwave popcorn. PFASs were detected in nine composites (four meat, three fish and shellfish, one fast food, and one microwave popcorn). PFOA and PFOS were most frequently found. The authors concluded that diet represented approximately 60% of total PFASs exposure. PFOA was detected in roast beef, pizza, and microwave popcorn at 0.74 to 3.6 ng/g, wet weight. The average daily PFOA exposure was estimated at 70 ng.

Several studies are available from countries in Western Europe with diets that are comparable to those in the United States. Fromme et al. (2007) collected duplicate diets for 15 male and 16 female healthy subjects (16 to 45 years old) in Germany. The median daily dietary intake for PFOA was 2.9 nanograms per kilogram of body weight (ng/kg) (232 ng/day for an 80 kg adult), with a 90th percentile intake of 672 ng/day. Haug et al. (2010) estimated exposures in Norway using a market basket approach comprised of 21 foods, three drinking water samples, one milk sample, and one tea sample. Total PFOA intake was estimated as 31 ng/day for the general Norwegian population. The highest levels were found in coffee, tea and cocoa (2.1 ng/day), root vegetables/potatoes (0.66 ng/day), tap water (0.54 ng/day), soft drinks (0.45 ng/day), and eggs (0.49 ng/day). Noorlander et al. (2011) estimated mean long-term daily intakes of 0.2 ng/kg (16 ng/day for an 80 kg adult) in the Netherlands using a pooled composite from foods purchased in retail chains with nationwide coverage; the 99th percentile value was 0.5 ng/kg (40 ng/day). Important sources were vegetables, fruits, and flour.

Human studies have shown that PFOA is transferred from mother to infant via cord blood and breast milk. A recent study showed that breast milk contributed > 83% of the PFOA exposure in 6-month-old infants (Haug et al. 2011). Additional information on concentrations of PFOA in breast milk is provided in section 2.5.

PFOA has been detected in beef as a result of cattle ingesting contaminated feed. When cattle were exposed to feed contaminated with 13 ng PFOA/kg wet weight, PFOA accumulated in the liver (9 ng/kg) and in muscle (7 ng/kg) (Vestergren et al. 2013). The study also detected PFOA
in cow’s milk at 6.7 ng/L. In addition, evidence suggests that livestock accumulate PFOA by grazing in fields where biosolids were applied (Renner 2009; Vestergren et al. 2013).

Bioaccumulation in fish and other edible aquatic organisms is another route for potential dietary exposures (Bhavsar et al. 2014; Renzi et al. 2013; Stahl et al. 2014). EPA analyzed fish fillet tissue samples from U.S. rivers and from the Great Lakes as part of EPA’s National Aquatic Resource Surveys. These analyses included characterizing perfluorinated compounds (PFCs) in freshwater fish on a national scale during EPA’s 2008–2009 National Rivers and Streams Assessment, and on a regional scale during the Great Lakes Human Health Fish Tissue Study component of the EPA 2010 National Coastal Condition Assessment. Fish were collected from randomly selected locations, including 162 urban river sites and 157 nearshore Great Lake sites, and analyzed for 13 PFASs. Results showed that 80% of urban river fish samples and 100% of Great Lakes fish samples contained some detectable PFASs. PFOS was the most frequently detected chemical (in 73% of river fish samples and 100% of Great Lakes fish samples). PFOA was not detected in river fish fillet samples, but it was detected in 12% of the Great Lakes samples. In the 2010 Great Lakes sampling, PFOA was detected in 19 out of 157 samples at a maximum concentration of 0.97 ng/g. The differences in PFOA detections between river and Great Lakes fish samples could be due to the availability of a more sensitive PFAS analytical method with lower detection limits when the Great Lakes study was initiated. Cooking of fish does not reduce the levels of PFOA in the fish (or the consumer’s dietary exposure) (Bhavsar et al. 2014).

PFOA has been detected in wild caught and farmed fish, presumably because of bioaccumulation and/or trophic transfer. Bhavsar et al. (2014) found that PFOA concentrations were higher in wild-caught fish than farmed fish, and suggested that fish caught near contaminated sites could represent an important exposure source among recreational and subsistence fishers.

In a survey of French adult freshwater anglers, PFOA was a major contributor of total PFAS exposure from fish. Although some individuals had higher exposures, overall values for this population were close to those for the general population (Denys et al. 2014). In a study of French adults who consumed large amounts of seafood (n = 993), mean lower bound exposure to PFOA was 1.16 ng/kg/day (92.8 ng/day for an 80 kg adult) compared to a lower bound of none in the general population (n = 1918). The mean upper bound values were 2.06 and 0.74 ng/kg/day (164.5 to 59.2 ng/day), respectively, for the same highly exposed and general population groups (Yamada et al. 2014). In a sub-study that was restricted to 106 pregnant women, the upper bound mean was 1.52 ng/kg/day (121.6 ng/day) and the 95th percentile upper bound was 2.41 ng/kg/bw/day (192.8 ng/day).

PFOA can occur in plants grown in soils containing PFOA. For example, PFOA was taken up by corn when grown in biosolid-amended soil; however, the chemical remained in the roots and did not accumulate in edible parts of the plant (Krippner et al. 2014). PFOA accumulation in fruit crops tends to be lower than in shoot or root crops, presumably because there are more compartments through which PFOA would have to pass to reach the edible portion of the plant (Blaine et al. 2014).
PFOA was previously used in the manufacturing of several types of food packaging; in January 2016, the U.S. Food and Drug Administration (FDA) amended its food additive regulations to no longer allow for the use of perfluoroalkyl ethyl-containing food-contact substances as oil and water repellants for paper and paperboard that comes in contact with aqueous and fatty foods (81 FR 5). PFOA is a breakdown product of the perfluorooctylethanol telomer alcohol used to make coatings for or additives in food contact paper where it adds a moisture or oil barrier to paper-type packaging, including microwave popcorn bags, fast food wrappers, candy wrappers, and pizza box liners (Begley et al. 2005). When used in this way, PFOA can migrate into foods from the packaging material. In a study conducted by FDA, Begley et al. (2005) was able to extract (4 micrograms per square decimeter [µg/dm²] paper) of PFOA into food oil before cooking and another 7 µg/dm² from paper after cooking. Based on these results, Begley et al. (2005) concluded that paper with treated coatings had a high potential for migration of fluorochemical to food.

Food can become contaminated with PFOA from preparation in nonstick cookware coated with polytetrafluoroethylene (PTFE) (Teflon™). PFOA is a processing aid in the manufacture of PTFE. Begley et al. (2005) also evaluated migration of PFOA to foods from cooking in Teflon™-lined cookware and found it to be much lower (0.03 µg/dm² polymer) than migration from coated paper. In this study, new pans leached more compared to those that had been used before.

### 2.2.4 Ambient Air

A number of PFASs are precursors of PFOA and degrade to PFOA in the environment via biotic and abiotic degradation. Some of these precursors are volatile and contribute to the formation of airborne PFOA. Indoor air sampling reportedly contains higher concentrations of these precursors than outdoor air (Vierke et al. 2012). Langer et al. (2010) reported detections of PFOA and precursors in indoor air samples from home residences and at stores that sold outdoor equipment, furniture, and carpet. Fraser et al. (2013) found that PFOA in serum was significantly correlated with air levels collected in offices, likely associated with carpeting, furniture, and paint.

PFOA can be emitted from nonstick cookware coated with PTFE. Schlummer et al. (2015) found that at typical cooking temperatures (< 230°C), perfluoroalkylcarboxylic acids (C4 to C12) dominated (4.75 ng per hour) by PFOA and perfluorobutanoic acid (PFBA) were released to the atmosphere; when pans were overheated PFBA and perfluoro-n-pentanoic acid (PFPeA) were dominant (> 260°C). Emissions were far greater at higher temperatures (12,190 ng per hour at 370 °C; Schlummer et al. 2015). Emissions are expected to decline with use of the product. The authors hypothesized that most of the emissions would end up in household dusts.

Based on its environmental fate properties, PFOA has low volatility. However, PFOA has been reported in ambient air, largely bound to particulate matter. It can be transported long distances via the atmosphere and has been detected at low concentrations in areas as remote as the Arctic (Shoeib et al. 2006) and Antarctic (Del Vento et al. 2012). PFOA levels in outdoor air were measured in a variety of locations, most of which are countries outside the United States. Fromme et al. (2009) reported mean levels of 2 picograms per cubic meter (pg/m³) in particulate matter for eight samples collected in the summer in Albany, New York with a mean of 3.2 pg/m³.
present in the gas phase. Mean air concentrations in Spain and England were 6.1 pg/m³ and 3.5 pg/m³, respectively (Beser et al. 2011; Goosey and Harrad 2012). In a study conducted in China, airborne PFOA concentrations were similar (Liu et al. 2015). Areas near wastewater treatment plants, waste incinerators, and landfills can be point sources for PFOA in outdoor air (Ahrens et al. 2011). PFOA-derived telomer alcohols can also be present in air (Jogsten et al. 2012).

2.2.5 Indoor Dust

Because of its widespread use in carpets, upholstered furniture, and other textiles, PFOA has been detected in indoor dust from homes, offices, vehicles, and other indoor spaces. Although some of these uses have been phased out, exposure could continue in legacy products and imported goods. As reported by Fraser et al. (2013), particulate matter from fabrics and carpeting are believed to be the source for the PFOA-containing dusts found in homes, offices, and automobiles.

A 2013 survey (Fraser et al. 2013) detected PFOA in samples of house dust (23.7 ng/g), office dust (32.0 ng/g), and vehicles (11.4 ng/g) collected at sites by 31 participants in Boston, Massachusetts. The Wisconsin Department of Health and Human Services collected vacuum cleaner contents from 39 homes as a means of evaluating the concentration of PFOA and 15 other PFASs in dust (Knobeloch et al. 2012). The median PFOA concentration was 44 ng/g. PFOA, PFOS and perfluorohexane sulfonate (PFHxS) accounted for about 70% of the total PFASs present in the dust. Lorber and Egeghy (2011) assessed Americans’ PFOA exposure and concluded that ingestion of household dust and food are primary routes of PFOA exposure for 2-year-old children. For median exposed children, exposures were estimated to be 13 and 8 ng/d from dust and food, respectively. For highly exposed children (at the 95th percentile), PFOA exposure from dust was estimated to be three times that from food.

Jogsten et al. (2012) collected dust samples from 10 selected homes in Catalonia, Spain, and analyzed them for 20 PFASs. All samples contained PFOA; the levels ranged from 1.5 to 13.9 ng/g. An important outcome of this study was the identification of PFOA volatile telomer alcohol derivatives in the dust samples at concentrations of up to 1.3 ng/g. The 8:2 telomer alcohols degrade metabolically to PFOA once ingested. A study conducted in Belgium also found that PFOA was present in home (median: 0.7 ng/g dry weight) and office dust (median: 2.2 ng/g dry weight) (D’Hollander et al. 2010). The highest of the indoor dust concentrations of those sampled (114 ng/g) were found in homes in Germany (Xu et al. 2013).

2.2.6 Soils

PFOA persists in soils near manufacturing facilities and disposal sites (Xiao et al. 2015) and in areas, such as military bases, where firefighting foams containing PFOA were heavily used (Filipovic et al. 2015). Measured concentrations of PFOA in surface soils range from 8.0 ng/g (Xiao et al. 2015) to 287 ng/g (Filipovic et al. 2015). These studies focused on two sites, the first in the Minneapolis–St. Paul, Minnesota, metropolitan area where PFASs were manufactured and disposed of, and the second on a former military airport in Sweden abandoned in 1994, where firefighting foams containing PFOA had been used. In both cases, there was ground water contamination. Xiao et al. (2015) determined that levels of PFOA in soils increased with depth,
providing evidence for migration into ground water (see also section 2.2.1). Filipovic et al. (2015) found that PFOA concentrations in soil cores remained high more than 30 years after usage was discontinued.

Incidental ingestion of soils represents a potential exposure route for PFOA. Regional and geographic differences in soil characteristics can influence PFOA concentrations. Soil contamination tends to occur at manufacturing sites of producers and users, where disposal of treated products has occurred (i.e., landfills), and potentially where biosolids containing PFASs are applied. Calculated residence time in soils suggests that persistence in the environment will extend well beyond the time that PFOA manufacturing ends (Zareitalabad et al. 2013). Contaminated soils also can be transported offsite via water and wind.

2.2.7 Biosolids

Biosolids are sometimes applied as an amendment to soils as fertilizers; in some cases, the biosolids can contain PFOA. For example, in May 2007, a Decatur, Alabama, manufacturer that used PFASs notified the Decatur Utilities Dry Creek Waste Water Treatment plant that it had unknowingly discharged large amounts of perfluorocarboxylic acid precursors (PFOA and perfluorododecanoic acid [PFDA]) to the utility (USEPA 2011a). The Decatur treatment plant also received wastewater from several other industries in the area that manufactured or used a variety of PFAS-containing materials. The incident was reported to EPA and other government agencies because biosolids from the wastewater plant had been applied to 5,000 acres of privately owned agricultural fields for the previous 12 years (1996 to 2008).

Testing revealed that the biosolids from the Decatur plant contained PFOA, PFOS and other PFASs. Concentrations in nine soil samples from the area ranged from 589 to 1,296 parts per billion (ppb) PFOA and 55 to 2,531 ppb PFOS. Subsequently, private wells, ponds, and other surface waters near the biosolids application sites were sampled and found to contain PFOS and PFOA, in some cases at levels greater than EPA’s provisional HA values. Several additional rounds of sample collection from the impacted areas confirmed the presence of PFASs, including PFOA and PFOS in the media tested (Lindstrom et al. 2011b; USEPA 2011a; Washington et al. 2010a, 2010b).

PFASs were not analyzed in the 2004 EPA Total National Sewage Sludge Survey (TNSSS), as analytical methods were not available when analytes were selected. Venkatesan and Halden (2013) re-analyzed archived samples for PFASs from the TNSSS in five composite samples, which represented 94 wastewater treatment facilities from 32 U.S. states and the District of Columbia in 2001. PFOS was the most abundant PFC identified (mean 403± 127 µg/kg dry weight), followed by PFOA (mean 34 ± 22 µg/kg dry weight). Armstrong et al. (2016) collected biosolid samples every 2 months from a large municipal water recovery facility between 2005 and 2013. The highest mean PFOA concentration reported was 23.5 µg/kg dry weight. Yoo et al. (2011) found PFOA and PFOS in plants (fescue, barley, bluegrass, and Bermuda grass) grown in soils amended with biosolids. Concentrations of PFOA ranged from 9.9 to 202.7 µg/kg. Concentrations in biosolids are expected to decline because of the phase-out of the use of PFOS and PFOA in manufacturing and industrial processes.


2.2.8 Consumer Products

Other materials that result in potential human exposure include legacy use and imported goods or continuing uses. Some examples of these uses are listed below.

- Stain/water repellants on clothing, bedding materials, upholstered furniture, carpets, and automobile interiors (e.g., Stainmaster™, Zonyl™, Nuva™, Unidyne™, Baygard™) (Walters and Santillo 2006); these materials can be a particularly important exposure route for infants and children because of their hand-to-mouth behaviors.
- Cooking surfaces (e.g., Teflon™)
- Toothpaste, shampoos, cosmetics
- Polishes and waxes
- Electronics
- Flame repellants
- Paints, varnishes, sealants
- Lubricants/surfactants/emulsifiers (continuing use)
- Food containers and contact paper\footnote{PFOA was used in some grease-proofing paper coatings or additives that can contribute to its presence in foods (Begley et al. 2005). However, in January 2016, FDA amended their food additive regulations to no longer allow for the use of perfluoroalkyl ethyl containing food-contact substances as oil and water repellants for paper and paperboard for use in contact with aqueous and fatty foods (81 FR 5).}
- Pesticide
- Aqueous film forming foams (continuing use; used for firefighting)
- Electronics
- Textiles (e.g., Gore-Tex™) and leather
- Plumbing tape
- Cleaning products

2.3 Environmental Fate

2.3.1 Mobility

PFOA is water soluble and has been found in surface water, ground water, and drinking water. It has low volatility in ionized form, but can adsorb to particles in air; because of its persistence, it can be transported long distances to the Arctic (Shoeib et al. 2006) and Antarctic (Del Vento et al. 2012). PFOA has a log K_{oc} of 2.06 and does not easily adsorb to sediments or aquifer materials; therefore, it tends to stay in the water column.

2.3.2 Persistence

PFOA is stable in the environment and resistant to hydrolysis, photolysis, volatilization, and biodegradation (see Table 2-1). No biodegradation or abiotic degradation processes have been found; the only dissipation mechanisms in water are dilution, advection, and sorption. Yamada et
al. (2005) determined that typical municipal waste incinerators destroy PFOA on textiles and paper and do not release it into the atmosphere.

2.3.3 Bioaccumulation

Several criteria can be used to assess bioaccumulation, including octanol-water partition coefficient ($K_{ow}$), bioconcentration factors (BCF), bioaccumulation factors (BAFs), and biomagnification or trophic magnification factors (BMFs or TMFs, respectively) (Gobas et al. 2009). The $K_{ow}$ and BCF metrics are typically based on partitioning of organic chemicals into octanol or lipids of biota. For PFOA, partitioning appears to be more related to protein binding properties than its lipid partitioning. Thus, the $K_{ow}$ is not a reliable measure of bioaccumulation potential for PFOA (EFSA 2008; UNEP 2015). Information from field studies, BCFs, BMFs, and TMFs provide the most conclusive evidence of accumulation of chemicals in food webs (Gobas et al. 2009) and are the more appropriate metrics for gauging the potential for accumulation of PFOA in fish, wildlife, and humans.

Because of the physical-chemical properties of PFOA, $K_{ow}$ cannot be reliably measured (Table 2-1; UNEP 2015; USEPA 2014b). Model estimates of $K_{ow}$ have been reported; however, verification that these chemicals are within the domain of the models is often not provided. Therefore, the validity of the use of such models is questionable (EFSA 2008; UNEP 2015). Available BCFs determined from lab studies have been reported and generally fall below traditional criteria used to assess bioaccumulation (e.g., Martin et al. 2003c). It is recognized, however, that BCFs determined by existing standard methods derived from lipid-partitioning are not an appropriate metric for assessing bioconcentration of PFOA (EFSA 2008; UNEP 2015). Although evidence of PFOA accumulation in many organisms has been documented, reported BAFs and BCFs for the chemical also fall below traditional criteria used to assess bioaccumulation potential (Loi et al. 2011; Martin et al. 2003a, 2003b; Morikawa et al. 2005; Quinete et al. 2009).

Field evidence of PFOA biomagnification, considered to be the preferable metric for assessing bioaccumulation potential (Gobas et al. 2009), has been documented in many organisms from many locations worldwide (UNEP 2015). Trophic magnification has also been evaluated (Environment Canada and Health Canada, 2012; Houde et al. 2006; Kelly et al. 2009; Loi et al. 2011; Martin et al. 2004). Some field trophic studies revealed TMFs greater than 1, which indicates that PFOA accumulated and increased in concentration with increasing trophic level; other studies reported TMFs less than 1 for some food webs. The weight of evidence for trophic magnification was deemed sufficient to consider PFOA to be bioaccumulative by the Stockholm Convention Persistent Organic Pollutants Review Committee (UNEP 2015).

2.4 Toxicokinetics

Uptake and egress of PFOA from cells is largely regulated by transporters in cell membranes (Anzai et al. 2006; Cheng et al. 2006; Klaassen and Aleksunes 2010; Nakagawa et al. 2007, 2009; Weaver et al. 2009, 2010; Yang et al. 2010). PFOA is absorbed from the gastrointestinal tract as indicated by the serum measurements in humans and treated animals. In serum, it is electrostatically bound to albumin, occupying nine to 12 sites, and sometimes displaces other substances such as nutrients and pharmaceuticals that normally would occupy a site (MacManus-
Spencer et al. 2009; Salvalaglio et al. 2010; Wu et al. 2009a). Linear PFOA chains display stronger binding than branched chains (Beesoon and Martin 2015). Binding causes a change in the conformation of serum albumin, thereby changing its affinity for the endogenous compounds it normally transports.

PFOA is distributed to tissues by a process requiring transporters. Accordingly, the tissue levels vary from organ to organ as demonstrated by Kemper (2003). The highest tissue concentrations are usually those in the liver. Liver accumulation in males is greater than that in females. Other tissues with a tendency to accumulate PFOA are the kidneys, lungs, heart, and muscle, plus the testes in males and uterus in females (Kemper, 2003). PFOA is not metabolized, thus any effects observed in laboratory toxicological studies are the result of parent compound, not metabolites.

Electrostatic interactions with proteins are an important toxicokinetic feature of PFOA. Studies demonstrate binding or interactions with receptors (e.g., peroxisome proliferator activated receptor alpha [PPARα], triiodothyronine [T3]), transport proteins and enzymes (Luebker et al. 2002; Weiss et al. 2009; L. Zhang et al. 2013). Saturable renal resorption of PFOA from the glomerular filtrate via transporters in the kidney tubules is a major contributor to the long half-life of this compound in humans (Nakagawa et al. 2007, 2009; Weaver et al. 2010; Yang et al. 2009, 2010). Branched-chain PFOAs are less likely to be resorbed than the linear molecules based on half-life information in humans (Y. Zhang et al. 2013). All toxicokinetic models for PFOA are built on the concept of saturable renal resorption first proposed by Andersen et al. (2006). Some PFOA is removed from the body with bile (Genuis et al. 2010), a process that also is transporter-dependent. Accordingly, the levels in fecal matter represent both unabsorbed material and material that is discharged to the intestines with bile.

During pregnancy, PFOA is present in the placenta and amniotic fluid in both animals (Fenton et al. 2009; Hinderliter et al. 2005) and humans (T. Zhang et al. 2013). Post-delivery, PFOA is transferred to offspring through lactation in a dose-related manner (Hinderliter et al. 2005, Fenton et al. 2009). Maternal serum levels decline as those in the pups increase. This also occurs in humans as demonstrated in the study by Mondal et al. (2014) of breastfeeding women and their infants in West Virginia and Ohio.

The half-life in humans for occupationally exposed workers (Olsen et al. 2007) was 3.8 years (95% CI [1.5, 9.1]). Bartell et al. (2010) determined an average half-life of 2.3 years based on a study of the decreases in human serum levels after treatment of drinking water for PFOA removal was instituted by the Lubeck Public Services District in West Virginia and the Little Hocking Water Association in Ohio. This is the value used for humans in this assessment because it applies to the general population and reflects humans whose exposure came primarily from their PWS. Half-lives are reported to be shorter in animals than for humans: 21 days (females) and 30 days (males) for monkeys (Butenhoff et al. 2004b); 11.5 days (males) and 3.4 hours (females) for Sprague-Dawley rats (Kemper 2003); 27.1 days (male) and 15.6 days (female) for CD-1 mice (Lau et al. 2006). Although the animal half-lives are shorter than humans, so, too, are their average lifetimes. In early life, the half-lives are nearly the same for both genders, but once the animals reach sexual maturity resorption increases in male rats, prolonging the half-lives (Hinderliter et al. 2006; Hundley et al. 2006). This change appears to be under the control of hormones in both males and females (Cheng et al. 2006; Kudo et al. 2002).
2.5 Human Biomonitoring Data

The Fourth National Report on Human Exposure to Environmental Chemicals from the Centers for Disease Control and Prevention (CDC 2009) included exposure data for PFOA from 2003 to 2004 collected by the National Health and Nutrition Examination Survey (NHANES). PFOA was detected in 99.7% of the general U.S. population. Since that time, CDC has issued several updates, the most recent of which was released in 2015 (CDC 2015). Taken together, the data suggest that PFOA concentrations in human serum in the U.S. generally declined between 1999 and 2012. The geometric mean PFOA concentration in human serum decreased from 5.2 to 2.1 μg/L, and the 95th percentile concentration decreased from 11.9 to 5.7 μg/L. During this time, there has been a major reduction in environmental emissions by the manufacturers as well as a phase-out of production of C-8 compounds in the United States. Analysis of the NHANES 2003–2004 subsample demonstrated higher levels of PFOA and PFOS in males and a slight increase in levels of PFOS with age (Calafat et al. 2007a, 2007b).

Precursors might also form PFOA in the body; this represent an important uncertainty in characterizing exposure as measured by blood serum. For example, Lorber and Egeghy (2011), indicated that the precursor fluorotelomer alcohols (FTOHs) and polyfluoroalkyl phosphoric acids (PAPs) would add to exposure but there is uncertainty as to the magnitude of the effect. The authors concluded that precursors “could very well contribute half or more of what is eventually measured as PFOA in the blood.”

Evidence shows that PFOA is distributed within the body and can be transferred from pregnant women to their unborn children and offspring. T. Zhang et al. (2013) collected serum and cord blood samples from 30 pregnant women in China. The maternal blood contained variable levels of 10 PFASs, eight acids, and two sulfonates. The mean maternal blood concentration for PFOA was 3.35 nanograms per milliliter (ng/mL). The mean was greater than the median, indicating a distribution skewed toward the higher concentrations. Compared to the mean PFOA blood levels in the pregnant women, the mean levels in cord blood (1.95 milligrams per milliliter [mg/mL]) was 47% of that in the mother’s blood.

PFOA has been detected in breast milk (Tao et al. 2008; Völkel et al. 2008) and cord blood (Apelberg et al. 2007; Monroy et al. 2008) at concentrations above the limit of quantification. Mondal et al. (2014) evaluated serum samples from breastfeeding women and their infants in West Virginia and Ohio. For each month of breastfeeding, maternal serum levels of PFOA were reduced by 3% (95% CI: 2%-5%) and infant serum levels increased by 6% (95% CI: 1%-10%). A publication from the French total diet study (Cariou et al. 2015) also examined human breast milk as an exposure route for infants using 61 mother-infant pairs. PFOA was detected in 77% of the breast milk samples, with a mean concentration of 0.041 ng/mL and a maximum concentration of 0.308 ng/mL. The regression coefficient for the association between the maternal serum concentration and the detected breast milk concentrations was 0.72 (n = 10).
3.0 PROBLEM FORMULATION

3.1 Conceptual Model

The conceptual model provides useful information to characterize and communicate the potential health risks related to PFOA exposure from drinking water. The sources of PFOA, the routes of exposure for biological receptors of concern (e.g., various human activities related to ingested tap water such as drinking, food preparation, and consumption), and the potential assessment endpoints (e.g., effects such as liver toxicity and developmental effects), and adverse health effects in the populations at risk due to exposure to PFOA are depicted in the conceptual diagram below (Figure 3-1).

Figure 3-1. Conceptual Model for PFOA in Finished Drinking Water
3.1.1 Conceptual Model Diagram for Exposure via finished Drinking Water

The conceptual model is intended to explore potential links of exposure to a contaminant or stressor with the adverse effects and toxicological endpoints important for management goals, including the development of drinking water HA values. Boxes that are more darkly shaded indicate pathways that were considered quantitatively in estimating the advisory level, whereas the lightly shaded boxes were only considered from a qualitative perspective.

3.1.2 Factors Considered in the Conceptual Model for PFOA

**Stressors:** For this HA, the stressor is PFOA in drinking water from public water facilities or private wells.

**Sources:** Sources of PFOA include both ground and surface waters used for drinking. Multiple potentially important sources of PFOA and precursors exist in addition to drinking water, such as foods, indoor dust in a home or work environment, indoor and outdoor air, soil, consumer products within the homes or place of work including children’s schools, and industrial products. The relative contribution of drinking water versus other sources is addressed in the Relative Source Contribution section of the document (section 3.2.5). This HA applies only to drinking water.

**Routes of exposure:** Exposure to PFOA from contaminated drinking water sources can occur via oral exposure (drinking water, cooking with water, and incidental ingestion from showering); dermal exposure (contact of exposed parts of the body with water containing PFOA during bathing or showering, dishwashing); and inhalation exposure (during bathing or showering or using a humidifier or vaporizer). There is limited information identifying health effects from inhalation or dermal exposures to PFOA in humans and animals. Therefore, these routes of exposure are not quantitatively used in the derivation of the HA. PFOA has a low vapor pressure and is not expected to be present in air except as bound to particulate matter and in aerosols formed from devices such as shower heads and humidifiers that aerosolize tap water. Toxicity data are available for oral exposure from drinking water, but not the other exposure routes (inhalation and dermal exposures). PFOA is not removed by heating water and can increase in concentration when the water is boiled.

**Receptors:** The receptors are those in the general population (adults, infants and children) who could be exposed to PFOA from tap water through dermal contact and inhalation and/or ingestion at their homes, workplaces, schools, and daycare centers.

**Endpoints:** Epidemiology data report associations between PFOA exposure and high cholesterol, increased liver enzymes, decreased vaccination response, thyroid disorders, pregnancy-induced hypertension and preeclampsia, and cancer (testicular and kidney) (see section 4.1.2). These studies provide varying levels of support for the effects associated with PFOA exposure in the animals studies used for quantification of the HA. Cholesterol, liver enzymes, and thyroid effects were examined in numerous studies in different populations, but the pregnancy complications of hypertension and preeclampsia in women and testicular cancer in young men were only studied in a high-exposure community (located in the vicinity of a PFOA production plant in West Virginia; i.e., C8 Health Project). The C8 Science Panel assessed the links between PFOA and several diseases and concluded that a probable link existed between...
PFOA and the observed kidney and testicular tumors among the population evaluated (see section 4.1.2).

The associations for most epidemiology endpoints are mixed. Although mean serum values are presented in the human studies, actual estimates of PFOA exposure (i.e., doses/duration) are not currently available. Thus, the serum level at which the effects were first manifest and whether the serum had achieved steady state at the point the effect occurred cannot be determined. It is likely that some of the human exposures that contribute to serum PFOA values come from PFOA derivatives or precursors that break down metabolically to PFOA. These compounds could originate from PFOA in diet and materials used in the home, which creates potential for confounding. In addition, most of the subjects of the epidemiology studies have many PFASs and/or other contaminants in their blood. Although the study designs adjust for other potential toxicants as confounding factors, their presence constitutes a level of uncertainty that is usually absent in the animal studies.

Taken together, the weight of evidence for human studies supports the conclusion that PFOA exposure is a human health hazard. At this time, EPA concludes that the human studies are adequate for use qualitatively in the identification hazard and are supportive of the findings in laboratory animals. EPA plans to begin another effort to determine the range of perfluoroalkyl compounds for which an Integrated Risk Information System (IRIS) assessment is needed, as indicated in the 2015 IRIS Multi Year Agenda.5

For PFOA, oral animal studies of short-term, subchronic, and chronic duration are available in multiple species including monkeys, rats, and mice (see section 4.1.1). Adverse effects observed following exposure to PFOA include liver toxicity (hypertrophy, necrosis, and effects on the metabolism and deposition of dietary lipids), kidney toxicity, and developmental effects (survival, body weight changes, reduced ossification, altered puberty, and retarded mammary gland development), immune effects, and cancer. EPA quantitatively evaluated (i.e., modeled serum concentrations) for the liver, developmental, immune, and cancer effects.

In most animal studies, changes in relative and/or absolute liver weight appears to be the most common effect observed with or without other hepatic indicators of adversity identifying increased liver weight as a common indicator of PFOA exposure. The liver also contains the highest levels of PFOA when analyzed after test animal sacrifice. The increases in liver weight and hypertrophy, however, also can be associated with activation of cellular PPARα receptors, making it difficult to determine if this change is a reflection of PPARα activation or an indication of PFOA toxicity. The PPARα response is greater in rodents than it is in humans. EPA evaluated liver disease and liver function resulting from PFOA exposure in studies where liver weight changes and other indicators of adversity such as necrosis, inflammation, fibrosis and/or steatosis (fat accumulation in the liver) or increases in liver or serum enzymes indicative of liver damage were observed. Only the doses associated with the adverse effects were used for the quantification of risk.

5 For more information on the IRIS agenda see https://www.epa.gov/iris/iris-agenda.
3.2 Analysis Plan

3.2.1 Health Advisory Guidelines

Assessment endpoints for HAs can be developed for both short-term (1-day and 10-day) and lifetime exposure periods using information on the noncarcinogenic and carcinogenic toxicological endpoints of concern. Where data are available, endpoints reflect susceptible and/or more highly exposed populations.

- A 1-day HA is typically calculated for an infant (0 to 12 months or a 10-kg child), assuming an acute exposure to the chemical; it is generally derived from a study of less than 7 days duration.
- A 10-day HA is typically calculated for an infant (0 to 12 months or a 10-kg child), assuming a limited period of exposure of 1 to 2 weeks; it is generally derived from a study of 7 to 30 days duration.
- A lifetime HA is derived for an adult (> 21 years old or an 80-kg adult), and assumes an exposure period over a lifetime (approximately 70 years). It is usually derived from a chronic study of 2 years duration, but subchronic studies can be used by adjusting the uncertainty factor employed in the calculation. For carcinogens, the HA documents typically provide the concentrations in drinking water associated with a range of risks (from one excess cancer case per 10,000 persons exposed to one excess cancer case per million persons exposed) for Group A and B carcinogens and those classified as known or likely carcinogens (USEPA 1986, 2005). Cancer risks are not provided for Group C carcinogens, or those classified as “suggestive,” unless the cancer risk has been quantified.

3.2.2 Establishing the Data Set

The Health Effects Support Document for Perfluorooctanoic Acid (PFOA) (USEPA 2016a) provides the health effects basis for development of the HA, including the science-based decisions providing the basis for estimating the point of departure (POD). To develop the HESD for PFOA, EPA assembled available information on toxicokinetics, acute, short-term, subchronic and chronic toxicity along with developmental and reproductive toxicity, neurotoxicity, immunotoxicity, genotoxicity and cancer in humans and animals. For a more detailed description of the literature review search and strategy for inclusion and exclusion of studies, see the Forward and Appendix A of the HESD for PFOA.

Briefly, through a literature search, studies were identified for retrieval, review, and inclusion in the document using the following criteria:

- The data contribute substantially to the weight of evidence for any of the toxicity endpoints.
- Elements of the study design merit its inclusion in the draft assessment based on its contribution to the mode of action (MOA) or the quantification approach.
- The study elucidates the MOA for any toxicity endpoint or toxicokinetic property associated with PFOA exposure.
- The effects observed differ from those in other studies with comparable protocols.
The study was relevant to drinking water exposures and to the U.S. population.

In addition, an evaluation of available data was performed by EPA to determine data acceptability. The following study quality considerations from U.S. EPA’s (2002) *A Review of the Reference Dose and Reference Concentration Processes* were used in selection of the studies for inclusion in the HESD and development of the HA.

- Clearly defines and states hypothesis.
- Adequately describes the study protocol, methods, and statistical analyses.
- Evaluates appropriate endpoints. Toxicity depends on the amount, duration, timing and pattern of exposure, and could range from frank effects (e.g., mortality) to more subtle biochemical, physiological, pathological or functional changes in multiple organs and tissues.
- Applies appropriate statistical procedures to determine an effect.
- Establishes dose-response relationship (i.e., no observed adverse effect level (NOAEL) and/or lowest observed adverse effect level (LOAEL) or data amenable to modeling of the dose response to identify a POD for a change in the effect considered to be adverse [out of the range of normal biological viability]. The NOAEL is the highest exposure level at which there are no biologically significant increases in the frequency or severity of adverse effects between the exposed population and its appropriate control. The LOAEL is the lowest exposure level at which there are biologically significant increases in frequency or severity of adverse effects between the exposed population and its appropriate control group.

The studies included in the HESD and HA were determined to provide the most current and comprehensive description of the toxicological properties of PFOA and the risk it poses to humans exposed through their drinking water.

After the available, reliable studies were evaluated for inclusion in the HESD and HA, critical studies were selected for consideration based on factors including exposure duration (comparable to the duration of the HAs being derived), route of exposure (e.g., oral exposure via drinking water, gavage, or diet), species sensitivity, comparison of the POD with other available studies demonstrating an effect, and confidence in the study (USEPA 1999). Uncertainty factors appropriate for the studies selected are then applied to the potential PODs to account for variability and uncertainty in the available data.

### 3.2.3 Approach for HA Calculation

For PFOA, toxicity and exposure data were used to develop a lifetime HA. EPA used measures of effect and estimates of exposure to derive the lifetime HA using the following three-step process:

**Step 1: Adopt a Reference Dose (RfD) or calculate an RfD using the appropriate point of departure (POD).** The RfD is an estimate (with uncertainty spanning perhaps an order of magnitude) of a daily human exposure to the human population (including sensitive subgroups) that is likely to be without an appreciable risk of deleterious effects during a lifetime. In the case of PFOA, the POD is the human equivalent dose (HED) derived from the modeled serum...
concentration representing either an NOAEL or LOAEL experimental dose after applying uncertainty factors established following EPA guidelines.

\[
\text{RfD} = \frac{\text{HED}_{\text{NOAEL}} \text{ or } \text{HED}_{\text{LOAEL}}}{\text{UF}}
\]

Where:

- \(\text{HED}_{\text{NOAEL}}\) = The HED from the modeled average serum representing the highest of the given doses that lacked adverse effects (mg/kg/day).
- \(\text{HED}_{\text{LOAEL}}\) = The HED from the modeled average serum representing the lowest of the given doses that results in adverse effects (mg/kg/day) and of an appropriate duration and endpoint to use for a lifetime HA.
- \(\text{UF}\) = Total Uncertainty Factor established in accordance with EPA guidelines considering variations in sensitivity among humans, differences between animals and humans, the duration of exposure in the key study compared to a lifetime of the species studied, whether the HED is a dose that caused an effect or no effect, and the completeness of the toxicology database.

**Step 2: Calculate a Drinking Water Equivalent Level (DWEL) from the RfD.** The DWEL assumes that 100% of the exposure comes from drinking water.

\[
\text{DWEL} = \frac{\text{RfD} \times \text{bw}}{\text{DWI}}
\]

Where:

- \(\text{RfD}\) = Reference dose (mg/kg bw/day)
- \(\text{bw}\) = Assumed body weight (kg)
- \(\text{DWI}\) = Assumed human daily drinking water intake (L/day)

**Step 3: Calculation of the Lifetime HA.** The lifetime HA is calculated by factoring in other sources of exposure (e.g., air, food, soil) in addition to drinking water using the methodology described for calculation of an RSC described in USEPA (2000) and section 6.1.

\[
\text{Lifetime HA} = \text{DWEL} \times \text{RSC}
\]

Where:

- \(\text{DWEL}\) = Drinking water equivalent level calculated from step 2 (mg/L)
- \(\text{RSC}\) = Relative source contribution

### 3.2.4 Measures of Effect

The animal toxicology studies were used in the dose-response assessment for PFOA. These studies demonstrated dose-related effects on systemic and developmental endpoints in multiple species (monkeys, rats, mice) following exposure to PFOA for durations of 11 to 84 days; these are described in detail in the HESD for PFOA. The studies selected for pharmacokinetic analysis were chosen based on their experimental design, data quality, dose-response data identified through the range of experimental NOAELs/LOAELs, and serum measurements of PFOA.
EPA used a peer-reviewed pharmacokinetic model developed by Wambaugh et al. (2013) to calculate the average serum concentrations associated with the candidate NOAELs and LOAELs from the toxicological database. Average serum levels of PFOA from the model were used to determine the HED associated with the study NOAEL and LOAEL. The Wambaugh et al. (2013) model is based on the Andersen et al. (2006) concept that saturable renal resorption is responsible for the long serum half-lives seen in humans and animals.

A unique feature of the pharmacokinetic approach is the use of a single model for the three species and reliance on the serum PFOA level as the measure of exposure. For each species the model accommodated the appropriate toxicokinetic variables for the species/strain. The pharmacokinetic analysis facilitated examination for consistency in the average serum values associated with effect and no-effect doses from the animal PFOA studies. A nonhierarchical model for parameter values was assumed wherein a single numeric value represented all individuals of the same species, gender, and strain. Body weight, the number of doses, and magnitude of the doses were the only parameters that varied.

3.2.5 Relative Source Contribution

The RSC is applied in the HA calculation to ensure that an individual’s total exposure from a contaminant (i.e., PFOA) does not exceed the RfD. The RSC is the portion of the RfD attributed to drinking water (directly or indirectly in beverages like coffee, tea, or soup); the remainder of the RfD is allocated to other potential exposure sources. In the case of PFOA, other potential sources include ambient air, foods, incidental soil/dust ingestion, consumer products, and others (see sections 2.2 and 6.1). The RSC for the HA is based on exposure to the general population.

EPA derived an RSC for PFOA by using the Exposure Decision Tree approach (USEPA 2000) (see section 6.1). To use that approach, EPA compiled information for PFOS on its uses, chemical and physical properties, occurrences in other potential sources (e.g., air, food), and releases to the environment. To determine the RSC to be used in the HA calculation for PFOA, EPA then used the information to address the questions posed in the Exposure Decision Tree. Some of the important items evaluated in the Exposure Decision Tree are:

- Adequacy of data available for each relevant exposure source and pathway.
- Availability of information sufficient to characterize the likelihood of exposure to relevant sources.
- Whether there are significant known or potential uses/sources other than the source of concern (i.e., ambient water and fish/seafood from those waters).
- Whether information on each source is available to characterize exposure.

In cases where environmental or exposure data are lacking, the Exposure Decision Tree approach results in a recommended RSC of 20%. This 20% RSC value may be replaced where sufficient data are available to develop a scientifically defensible alternative value. When appropriate, if scientific data demonstrating that sources and routes of exposure other than drinking water are not anticipated for the pollutant in question, the RSC may be raised to 80% based on the available data (USEPA 2000).
4.0 EFFECTS ASSESSMENT

The database for PFOA includes a large number of laboratory animal toxicity studies, as well as numerous epidemiology studies. The most extensive epidemiology studies were conducted by the C8 Science Panel for a highly exposed population in West Virginia. These animal and human studies are described below and in greater detail in the HESD for PFOA (USEPA 2016a). Because of uncertainties associated with the human data (described above), EPA is relying on animal data to quantitatively assess effects; however, the epidemiology studies provide important data to establish probable links between PFOA exposure to humans and health effects. In particular, effects on the liver enzymes indicative of liver effects, low birthweight, antibody response, and cancer in laboratory animals are supported by human epidemiology studies.

4.1 Noncancer Health Effects

4.1.1 Animal Toxicity Studies

The database of animal toxicology studies is extensive with short term, subchronic, and chronic toxicity and cancer studies; developmental and reproductive toxicity, neurotoxicity, and immunotoxicity studies; and mechanistic studies.

Developmental Effects

Both rats and mice showed developmental toxicity based on low birth weights, skeletal effects (reduced ossification), altered onset of puberty (Butenhoff et al. 2004a; Lau et al. 2006; Wolf et al. 2007). Doses that elicited a response were higher in rats compared with those in mice. Meta-analyses were conducted to determine whether developmental exposure to PFOA was associated with fetal growth effects in animals (Koustas et al. 2014). Eight animal studies identified in the published literature met the criteria of the Navigation Guide systematic review methodology as developed and published by Woodruff and Sutton (2014) for inclusion in the analyses. The animal data sets included mouse gavage studies with maternal PFOA doses from 0.01 to 20 mg/kg/day. The results from the meta-analysis showed that a 1 mg/kg/day increase in PFOA dose was associated with a \(-0.023\) g (95% CI \([-0.029, -0.016]\)) difference in pup birth weight. The MOA for decreased pup body weight is not known, but receptor-activated changes in metabolism, hormonal perturbations, and impeded intercellular communication might play a role.

One animal neurological study (Johansson et al. 2009) showed effects on habituation and activity patterns in NMRI (Naval Medical Research Institute) mice treated on post-natal day (PND)10 with a single dose of PFOA and evaluated at 2 and 4 months of age (LOAEL = 0.58 mg/kg). The in vivo observations are supported by changes in the expression of a variety of neurologically active brain proteins in the treated pups (Johansson et al. 2009). The offspring of C57BL/6/Bkl dams fed diets that provided a dose of 0.3 mg PFOA/kg/day throughout gestation had detectable levels of PFOA in their brains at birth (Onishchenko et al. 2011). Behavioral assessments of the offspring starting at 5 weeks of age revealed sex-related differences in exploratory behavior patterns. In the social group setting, the PFOA-exposed males were more active and PFOA-exposed females were less active than their respective controls. The PFOA-exposed males also had increased activity counts compared to control males in circadian activity...
The results of an *in vitro* study of hippocampal synaptic transmission and neurite growth in the presence of long chain perfluorinated compounds showed that 50 or 100 micromolar PFOA increased spontaneous synaptic current and had an equivocal impact on neurite growth (Liao et al. 2009a, 2009b). These data suggest a need for additional studies of the effects of PFASs, including PFOA, on the brain.

The developmental impacts of PFOA exposure ranged from delayed mammary gland development in pups (Albrecht et al. 2013; Macon et al. 2011; Tucker et al. 2015; White et al. 2009, 2011; Wolf et al. 2007) to delays in attaining developmental milestones (Lau et al. 2006; White et al. 2009; Wolf et al. 2007). The LOAEL for the mammary gland developmental effects in female offspring from dams given 0.01 mg/kg/day for 8 days from Macon et al. (2011) is of unknown biological significance. The same study showed no effects on offspring body weight at maternal doses up to 3 mg/kg/day for 17 days (Macon et al. 2011). Data from White et al. (2011) showed no significant effects on body weight gain in pups nursing from dams treated with 1 mg/kg/day, despite these dams having less fully developed mammary glands compared to controls. Similarly, no differences in response to a lactational challenge were seen in PFOA exposed dams with morphologically delayed mammary gland development (White et al. 2011).

**Immune Function**

Several animal studies demonstrate effects on the spleen and thymus as well as their cellular products (B lymphocytes and T-helper cells) in several strains of mice. Studies by Yang et al. (2000, 2001, 2002b) and DeWitt et al. (2008) were conducted using relatively high PFOA doses (~30 to 40 mg/kg/day). In each study, the PFOA-treated animals exhibited significant decreases in spleen and thymus weights as well as splenocyte and thymocyte populations at various stages of differentiation. Recovery usually occurred within several days of cessation of PFOA dosing. When the response of C57BL/6Tac PPARα mice were compared to wild type of the same strain, the knockout mice showed no response with both spleen and thymus weights at 30 mg/kg/day, whereas there was a response in the wild-type strain (DeWitt et al. 2015), suggesting an impact of PPARα. Both strains showed an increase in immunoglobulin M (IgM) in response to a sheep red blood cell (SRBC) injection. The 30 mg/kg/day dose was the LOAEL for the knockout mice and 7.5 mg/kg/day was the response level for the wild-type strain. Thus, the suppression of the immune system is not totally a PPARα-related response.

DeWitt et al. (2008) used different functionality assays in their study in C57Bl/6 mice. The IgM response to SRBCs was suppressed by 20% when mice were immunized immediately after exposure to the initial dose of 30 mg PFOA/kg/day ceased. However, no significant increase occurred in the response to bovine serum albumin 4 days post-PFOA exposure, or in the immunoglobulin G (IgG) response to SRBC 15 days post-PFOA exposure. These results are indicative of recovery once PFOA exposures have ceased. DeWitt et al. (2008) followed their initial study of PFOA with one designed to examine the dose response for a 15-day drinking water exposure in a slightly different mouse strain, C57Bl/6N. The LOAEL was 3.75 mg/kg/day based on a significant decrease in IgM response, and the NOAEL was 1.88 mg/kg/day indicating the inability to respond to an immunological challenge.
Liver Disease and Liver Function

Hepatocellular hypertrophy and an increased liver-to-body weight ratio are common findings in rodents, but are considered non-adverse if there is evidence for PPARα activation. These effects are considered adverse if accompanied by necrosis, fibrosis, inflammation, and steatosis (Hall et al. 2012). Low-level necrotic cell damage was observed in the Palazzolo et al. (1993) rat study and in the Loveless et al. (2008) studies in CD rats and CD-1 mice. Palazzo et al. (1993) is an unpublished report that was later published as Perkins et al. (2004). The liver histopathology details of this study were only presented in Palazzolo et al. (1993). This study will be referred to throughout the rest of the document as Palazzolo et al. (1993)/Perkins et al. (2004). In this study there was a slight increase in coagulative necrosis at 1.94 and 6.5 mg/kg/day when compared to the control and lower dose (0.94 mg/kg/day). Some hepatocellular necrosis was also observed in conjunction with hepatocellular hypertrophy and increased liver weight at a dose of 3 mg/kg/day in F1 male rats from the Butenhoff et al. (2004a) two-generation study.

In general, effects on organs other than the liver tend to occur at doses higher than those that affect the liver. Lung effects including pulmonary congestion were observed in male Sprague-Dawley rats (LOAEL = 5 mg/kg/day) by Cui et al. (2009). Increased thickness and prominence of the adrenal zona glomerulosa and vacuolization in the cells of the adrenal cortex were observed in male rats fed 10 mg/kg/day for approximately 56 days (Butenhoff et al. 2004a).

Kidney Function

Some studies have shown effects on the kidney of male rats at doses similar to those resulting in liver effects. Increases in absolute and relative-to-body kidney weights occurred in rats given 5 mg/kg/day (lowest dose tested) via gavage for 28 days (Cui et al. 2009). In a two-generation gavage study, F0 and F1 males had significantly increased absolute kidney weight at 1 and 3 mg/kg/day, but significantly decreased kidney weight at 30 mg/kg/day. Organ weight-to-terminal body weight ratios for the kidney were statistically significantly increased at ≥ 1 mg/kg/day. Kidney weight-to-brain weight ratios were significantly increased at 1, 3, and 10 mg/kg/day, but decreased at 30 mg/kg/day (Butenhoff et al. 2004a). In the high-dose group, absolute and relative kidney weight changes occurred in a pattern typically associated with decrements in body weight and are indicative of systemic toxicity. In the lower-dose groups, the consistently increased absolute and relative to body and brain weights suggest a cellular response, whereby the kidney tubular cells upregulate expression of transporter proteins to facilitate the PFOA excretion. This is adverse because it is a biomarker for systemic PFOA bioaccumulation. The differential expression of transporters in the kidney of male rats is under hormonal control with males having lower levels of export transporters compared to females (Kudo et al. 2002). No dose-related changes in kidney weight or histopathology were found in male rats at the end of 2 years with a dose of 14.2 mg/kg/day (Butenhoff et al. 2012).

Diabetes

Hines et al. (2009) found no differences in glucose tolerance tests at 15–16 weeks and at 17 months of age in PFOA-exposed CD-1 mice, but did observe significantly increased serum leptin and insulin levels at 21 and 31 weeks of age suggesting that the insulin resistance mechanistic pathway could be affected by PFOA and a connection between PFOA and increased body weight. Leptin is a hormone secreted by adipose tissue that is associated with weight gain.
Conversely, Quist et al. (2015) found no dose-related impact on serum leptin in CD-1 pups on PND 91. Quist et al. (2015) found that when mice were on a high-fat diet and not fasted before serum collection and these were compared to the same mice that were fasted before serum collection, leptin increased, thereby suggesting that the leptin change could be temporary and dependent on the fat content of the diet and the timing of serum collection.

Thyroid

Effects of PFOA on thyroid hormones in animals are not as well characterized as those of PFOS. Butenhoff et al. (2002) evaluated the toxicity of PFOA in a small number of male monkeys during 6 months of oral administration and reported that levels of total T3 and free T3 in circulation were reduced significantly in the 30/20 mg/kg/day treatment group, beginning at 5 weeks after initiation of treatment but accompanied by other signs of systemic toxicity. Recovery of T3 deficits was noted when PFOA returned to baseline 90 days later. Serum total thyroxine (T4), free T4, and thyroid-stimulating hormone (TSH) were not altered throughout the study. The preferential effects of PFOA on serum T3 and a lack of a TSH compensatory response are similar to those observed with PFOS, and are possibly a consequence of PFOA binding to the T3 receptor (Ren et al. 2015). None of the thyroid hormones were affected by PFOA in mature female rats (Butenhoff et al 2002), primarily because these animals were able to clear the chemical effectively (with half-life estimate of 2 to 4 hours, compared to that of 6 to 7 days for male rats). This suggests that the thyroid disrupting effects of PFOA are directly related to endogenous accumulation of the chemical and might be relevant to humans because of the long PFOA human half-life.

Fertility, Pregnancy, and Birth Outcomes

Among animal studies there was no effect of PFOA on reproductive or fertility parameters in rats (Butenhoff et al. 2004a), but effects on male fertility were observed in mice given a dose of 5 mg/kg/day for 28 days prior to mating (Lu et al. 2015). A NOAEL of 2.5 mg/kg/day and a LOAEL of 5 mg/kg/day were reported for reduced sperm counts and changes in testicular morphology after a 14-day exposure by Liu et al. (2015); 2 mg/kg/day led to significantly increased serum estradiol and increased hepatic aromatase activity in the same study. Gender differences in dose response are likely related to half-life differences of hours for the female rat and days-to-weeks for the female mouse.

Serum Lipids

Information on serum lipids from animal studies has received less attention than in the human population because decreases in triglycerides, cholesterol, and lipoprotein complexes are an expected consequence of PPARα activation in rodents. PFOA is an activator of the PPARα nuclear receptor in both humans and animals, but activation in humans does not increase the cellular levels of peroxisomes to the same extent it does in rodents. The PPARα response in animals tends to lower rather than raise serum cholesterol and associated lipid levels. PFOA is known to activate the PPAR pathway by increasing transcription of mitochondrial and peroxisomal lipid metabolism, sterol, and bile acid biosynthesis and retinol metabolism genes. However, based on transcriptional activation of many genes in PPARα null mice, the effects of PFOA involve more than activation of PPAR. Also activated are the constitutive androstane receptor (CAR), farnesoid X receptor (FXR), and pregnane X receptor (PXR).
Cholesterol and/or triglycerides were monitored in few animal studies. Nakamura et al. (2009) found that mice with a normal PPARα receptor had significantly increased levels of cholesterol and triglycerides in liver, but not plasma, at a LOAEL of 0.3 mg/kg/day. However, no differences were observed in serum or liver cholesterol or triglycerides between PFOA-treated mice with a humanized PPARα receptor or PPARα null mice (NOAEL = 0.3 mg/kg/day) and their respective controls. A study by Minata et al. (2010) used higher doses and found that total cholesterol was significantly decreased and total triglycerides significantly increased in wild-type mice. In the PPARα null mice, total triglycerides were significantly increased at all doses.

In animal studies, serum levels of alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) were significantly increased indicative of apoptosis or necrosis of liver cells (Butenhoff et al. 2012; Minata et al. 2010; Son et al. 2008). Increased levels of ALT were observed at a LOAEL of 2.65 mg/kg/day in ICR mice by Son et al. (2008). Yahia et al. (2010) reported significantly increased ALT, gamma-glutamyl transferase (GGT), AST, and alkaline phosphatase (ALP) in PFOA-exposed (10 mg/kg) pregnant ICR mice. Total protein, albumin, and globulin were significantly decreased in the same mice.

### 4.1.2 Human Epidemiology Studies

Numerous epidemiology studies evaluating large cohorts of highly exposed occupational and general populations have examined the association of PFOA exposure to a variety of health endpoints. Health outcomes assessed include blood lipid and clinical chemistry profiles; reproductive parameters; thyroid effects; diabetes; immune function; birth, fetal, and developmental growth measures; and cancer. Members of the general population living in the vicinity of the West Virginia DuPont Washington Works PFOA production plant in Parkersburg, West Virginia, are the focus of an ongoing study titled the C8 Health Project. Releases from the Washington Works plant, where PFOA was used as a processing aid in the manufacture of fluoropolymers, contaminated the ground water from six water districts near the plant, resulting in exposures to the general population. The C8 Health Project is the largest study evaluating human exposure and health endpoints for PFOA; the study included more than 65,000 people in Mid-Ohio Valley communities who were exposed to PFOA for longer than 1 year.

As part of the C8 Health Project, a panel of expert epidemiologists reviewed the epidemiological and other data available in 2011 and 2012 to assess probable links between PFOA exposure and disease. The C8 Science Panel concluded that a probable link existed between PFOA exposure and the following conditions: high cholesterol, thyroid disease, pregnancy-induced hypertension, ulcerative colitis, and kidney and testicular cancer. The C8 Science Panel did not find a probable link between PFOA exposure and multiple other conditions, including other autoimmune diseases (rheumatoid arthritis, lupus, Type I diabetes, Crohn’s disease, multiple sclerosis), Type II diabetes, high blood pressure, coronary artery disease, infectious disease, liver disease, Parkinson’s disease, osteoarthritis, neurodevelopmental disorders in children (attention deficit hyperactivity disorder, learning disabilities), chronic kidney disease, stroke, asthma or chronic obstructive airways disease (COPD), and birth defects.

---

6 For more information see [http://www.c8sciencepanel.org/prob.link.html](http://www.c8sciencepanel.org/prob.link.html).
miscarriage or stillbirth, preterm birth or low birth weight, and other types of cancer. The summary below focuses on the endpoints highlighted as “probable links” by the C8 Science panel, and on other epidemiology studies published after the 2011–2012 reports.

Serum Lipids

The association between PFOA and serum lipids has been examined in several studies in different populations. Cross-sectional and longitudinal studies in occupational settings (Costa et al. 2009; Olsen et al. 2000, 2003; Olsen and Zobel, 2007; Sakr et al. 2007a, 2007b; Steenland et al. 2015) and in the high-exposure community (the C8 Health Project study population) (Fitz-Simon et al. 2013; Frisbee et al. 2010; Steenland et al. 2009; Winquist and Steenland 2014a) generally observed positive associations between serum PFOA and total cholesterol in adults and children (ages 1 to < 18 years); most of these effect estimates were statistically significant. Although exceptions to this pattern are present (i.e., some of the analyses examining incidence of self-reported high cholesterol based on medication use in Winquist and Steenland, 2014a, and in Steenland et al. 2015), the results are relatively consistent and robust. Similar associations were seen in analyses of low-density lipoprotein (LDL), but were not seen with high-density lipoprotein (HDL). The range of exposure in occupational studies is large (means varying between 0.4 and > 12 micrograms per milliliter [µg/mL]), and the mean serum levels in the C8 population studies were around 0.08 µg/mL. Positive associations between serum PFOA and total cholesterol (i.e., increasing lipid level with increasing PFOA) were observed in most of the general population studies at mean exposure levels of 0.002 to 0.007 µg/mL (Eriksen et al. 2013; Fisher et al. 2013; Geiger et al. 2014; Nelson et al. 2010; Starling et al. 2014). The interpretation of these general population results is limited, however, by the moderately strong correlations (Spearman r > 0.6) and similarity in results seen for PFOS and PFOA.

Liver Disease and Liver Function

Few studies pertaining to the relation between PFOA and liver disease are available. The C8 Health Project did not observe associations with hepatitis, fatty liver disease, or other types of liver disease. In the studies of PFOA exposure and liver enzymes (measure in serum), positive associations were seen. The results of the occupational studies provide evidence of an association with increases in serum AST, ALT, and GGT, with the most consistent results seen for ALT. The associations were not large, and the associations could depend on the co-variates in the models, such as body mass index, use of lipid lowering medications, and triglycerides (Costa et al. 2009; Olsen et al. 2000, 2003; Olsen and Zobel, 2007; Sakr et al. 2007a, 2007b).

Two population-based studies of highly exposed C8 area residents evaluated associations with liver enzymes, and the larger of the two studies reported associations of increasing serum ln ALT and ln GGT levels with increasing serum PFOA concentrations (Emmett et al. 2006; Gallo et al. 2012). A cross-sectional analysis of data from NHANES, representative of the U.S. national population, also found associations with ln PFOA concentration with increasing serum ALT and ln GGT levels. Serum bilirubin was inversely associated with serum PFOA in the occupational studies. A U-shaped exposure-response pattern for serum bilirubin was observed among the participants in the C8 Health Project which might explain the inverse associations reported for occupational cohorts. Overall, an association of serum PFOA concentration with elevations in serum levels of ALT and GGT was consistently observed in occupational, highly
exposed residential communities, and the U.S. general population. The associations are not large in magnitude, but indicate the potential to affect liver cells.

**Immune Function**

Three studies examined associations between maternal and/or child serum PFOA levels and vaccine response (measured by antibody levels) in children (Grandjean et al. 2012; Granum et al. 2013) and adults (Looker et al. 2014). The study in adults was part of the high-exposure community C8 Health Project; a reduced antibody response to one of the three influenza strains tested after receiving the flu vaccine was seen with increasing levels of serum PFOA. The studies in children were conducted in general populations in Norway and in the Faroe Islands. As observed in the animal studies, decreased vaccine response in relation to PFOA levels was seen in these studies, but similar results also were seen with other correlated PFASs (e.g., PFOS).

**Thyroid**

Three studies reported an increased risk of thyroid disease in women or girls, but not men (Lopez-Espinosa et al. 2012; Melzer et al. 2010; Winquist and Steenland, 2014b). A fourth study also reported a trend of elevated TSH and decreased T4 (hypothyroidism) in pregnant women testing positive for hypothyroid autoimmune disease (Webster et al. 2014). Similarly, the C8 Panel concluded there was strong evidence to link PFOA exposure to thyroid disease in its population. Hypothyroxinemia (decreased free thyroxine (FT4) without concomitant elevation of TSH) was measured in one study of pregnant women showing null findings for hypothyroxinemia incidence versus controls; hypothyroxinemia is not typically studied in the clinic as TSH and T4 concomitantly inversely shift with thyroid disease. Looking at thyroid hormone levels, some studies found changes in thyroid hormone levels associated with PFOA (de Cock et al. 2014; Shrestha et al. 2015; Webster et al. 2014; Wen et al. 2013,); others found null effects of PFOA in association with thyroid hormones. Generally null associations were found in other studies on the general population, pregnant women, and patients in association with thyroid hormone levels or one portion of the thyroid panel was outside of control range. Across multiple studies, thyroid hormone concentrations have mixed evidence (associations and null findings) in association with PFOA concentrations. Increased risk for thyroid disease in women appears to be associated with PFOA serum concentration; evidence is weaker or null in men.

**Diabetes**

No associations were observed between serum PFOA levels and type II diabetes incidence rate in general or worker populations with mean serum PFOA up to 0.0913–0.113 µg/mL (MacNeil et al. 2009; Steenland et al. 2015). PFOA was not associated with measures of metabolic syndrome in adolescents or adults (Lin et al. 2009). However, one study found an increased risk for developing gestational diabetes in women with mean serum PFOA (measured at preconception) of 0.00394 µg/mL (Zhang et al. 2015).

**Fertility, Pregnancy, and Birth Outcomes**

The association between PFOA and birth weight has been examined in numerous studies (see section 4.1.1.7 in USEPA 2016a). Most studies measured PFOA in the general population using
maternal blood samples taken in the second or third trimester or in cord blood samples. One study was able to collect samples earlier in the pregnancy (4–14 weeks) (Fei et al. 2007), and another study in the high-exposure community (the C8 Health Project population) modeled exposure based on data on residential history and environmental data (Savitz et al. 2012). Two meta-analyses of these studies have been conducted (Johnson et al. 2014; Verner et al. 2015), with similar results: mean birthweight reduction of 19 g (95% CI [-30, -9]) per each one unit (ng/mL) increase in maternal or cord serum PFOA levels in Johnson et al. (2014), and a mean birthweight reduction of 15 g (95% CI [-22, -8]) based on seven of these nine studies in Verner et al. (2015). It has been suggested that low glomerular filtration rate (GFR) can affect birth weight (Morken et al. 2014). Verner et al (2015) conducted a meta-analysis based on physiologically based pharmacokinetic model (PBPK) simulations and found that some of the association reported between PFOA and birth weight is attributable to GFR and that the actual association may be closer to a 7 gram reduction (95% CI [-8, -6]). Verner et al. (2015) showed that in individuals with low GFR there are increased levels of serum PFOA and lower birth weights. Although some uncertainty exists in the interpretation of the observed association between PFOA and birth weight given the potential impact of low GFR, the available information indicate that the association between PFOA exposure and birth weight cannot be ruled out. In humans with low GFR (which includes women with pregnancy-induced hypertension or preeclampsia) the impact on body weight is likely due to a combination of the low GFR and the serum PFOA.

Two studies examined development of puberty in girls in relation to prenatal exposure to PFOA as measured through maternal or cord blood samples in follow-up of pregnancy cohorts conducted in England (Christensen et al. 2011) and in Denmark (Kristensen et al. 2013). The results of these two studies are conflicting, with no association (or a possible indication of an earlier menarche seen with higher PFOA) in Christensen et al. (2011), and a later menarche seen with higher PFOA in Kristensen et al. (2013). Another study examined PFOA exposure measured concurrently with the assessment of pubertal status (Lopez-Espinosa et al. 2011). An association between later age at menarche and higher PFOA levels was observed, but the interpretation of this finding is complicated by the potential effect of puberty on the exposure biomarker levels (i.e., reverse causality). Menstruation is a route of excretion for albumin-bound PFOA; thus, the beginning of menstruation will remove serum PFOA when the menstruation periods begin during puberty and its cessation at menarche will decrease the loss of PFOA in blood and allow serum levels to increase.

Limited data suggest a correlation between higher PFOA levels (>0.02 µg/mL) in women and decreases in fecundity and fertility (Fei et al. 2009; Vélez et al. 2015), but there are no clear effects of PFOA on male fertility endpoints (0.0035–0.005 µg/mL; Joensen et al. 2009, 2013).

### 4.1.3 Noncancer Mode of Action

No published cohesive MOA exists that accounts for the varied toxicological properties of PFOA. However, a number of the unique properties of the compound contribute to its toxicity:

- Metabolic stability accompanied by persistence in tissues as an apparent consequence of saturable renal resorption.
• Electrostatic binding to biopolymers with areas of positive charge, especially proteins (MacManus-Spencer et al. 2009; Salvalaglio et al. 2010; Wu et al. 2009b; L. Zhang et al. 2013).

• Displacement of endogenous/exogenous substances normally bound to serum albumin such as fatty acids, bile acids, pharmaceuticals, and T3 (Fasano et al. 2005; Qin et al. 2010; Wu et al. 2009a).

• Renal resorption (Andersen et al. 2006) and biliary excretion that are dependent on transporters genetically encoded for management of natural substances (endogenous and exogenous) that prolong systemic retention of absorbed PFOS and explain its long half-life.

• Binding to and activating receptors such as PPAR, thereby initiating activation or suppression of gene transcription related to fatty acid metabolism and lipid transport (Nakamura et al. 2009; Rosen et al. 2007, 2009a, 2009b; Takacs and Abbott 2007).

• Interference with intercellular communication (Upham et al. 1998, 2009).

The renal resorption and biliary competition between natural substrates and PFAS contribute to ambiguity in some of the epidemiology study outcomes where serum levels of endogenous or dietary-transported substrates are altered because of preferential removal or resorption of the PFOA, or the PFOA serum level increases because of the preferred excretion of the natural material. Physiological status also has an impact on the epidemiology results given that blood loss through menstruation is an excretory pathway for serum-albumin-bound PFOA. Thus, serum levels will be lower in girls after puberty than before, and will increase in women after menopause. In pregnant women, increased blood volume as well as cessation of monthly menstrual blood flow route also influences serum levels.

The outcome from studies of antibodies or immunoglobulins can be confounded by PFOA protein binding depending on the impact of morphological changes caused by PFOA binding on the sensitivity of the assay. Interaction of PFOA and other PFASs (Ren et al. 2015) with the T3 receptor has the potential to influence cellular uptake of T3. Binding to thyroid hormone transport protein or transthyretin (TTR) can displace T4 increasing the unbound level in serum (Weiss et al. 2009).

There are no cohesive studies designed to identify modes of action for the liver weight and hypertrophy endpoints represented in the animal studies. Both effects are clearly, in part, an outcome of PPARα activation. They become adverse when accompanied by inflammation, fibrosis, steatosis, or necrosis (Hall et al. 2012) as seen in Palazzolo et al. (1993)/Perkins et al. (2004), Loveless et al. (2008), and Butenhoff et al. (2004a).

The MOA for decreased pup body weight observed in the animal studies is unknown (Butenhoff et al. 2004a; White et al. 2009; Wolf et al. 2007). The observed effects on birth weight in animals are supported by evidence of an association between PFOA and low birth weight in humans (Johnson et al. 2014). Receptor-activated changes in metabolism, hormonal perturbations, and impeded intercellular communication could play a role in this effect. It has been suggested that GFR can affect birth weight (Morken et al 2014). Verner et al. (2015) conducted a meta-analysis based on PBPK simulations and found that some of the association reported between PFOA and birth weight could be partially attributable to low GFR and that the actual association might be closer to a 7 gram reduction (95% CI [-8, -6]). However, the study
authors demonstrated that individuals with low GFR have increased levels of serum PFOA and lower birth weights. Although some uncertainty exists in the interpretation of the observed association between PFOA and birth weight given the potential impact of low GFR, the available information indicate that the association between PFOA exposure and birth weight cannot be ruled out. In humans with low GFR (which includes women with pregnancy-induced hypertension or preeclampsia) the impact on body weight is likely due to a combination of the low GFR and the serum PFOA.

Women with hypertension during pregnancy are a susceptible population that could have an increased risk for having a low birth weight baby.

There also is a lack of data relative to the MOA for immunological effects of PFOA as seen in animal studies. Some of the responses are PPARα linked (increased spleen and thymus weights) but not all as demonstrated by DeWitt et al. (2015). Effects on serum immunoglobulins observed in humans could be a reflection of analytical method interference as a result of PFOA binding to the immunoglobin (Kerstner-Wood et al. 2003).

PFOA is associated with delayed breast tissue development (reduced ductal branching and numbers of terminal endbuds) in CD-1 mice (Albrecht et al. 2013; Macon et al. 2011; Tucker et al. 2015; White et al. 2009); however, no functional impacts on the ability of the dams to provide nourishment were observed based on the weight increases in the pups reared by the impacted dams (Macon et al. 2011; White et al. 2011). CD-1 mice seem to be more sensitive for this effect than other mice strains evaluated (Tucker et al. 2015). No mechanistic studies exist that inform the MOA for the mammary gland development effects.

Quist et al. (2015) found that the level of dietary fat in an animal diet is an important variable that influences liver lipid levels. At PFOA doses < 0.3 mg/kg/day, the LDL and total serum cholesterol levels in the fasted and nonfasted high-fat diet animals were greater than in the untreated Purina controls. Tan et al. (2013) found that the fat content of the diet was an important variable in determining the impact of PFOA (5 mg/kg/day) on liver and serum lipids. Intake of a high-fat diet plus PFOA increased liver triglycerides and serum free fatty acids as compared to a regular fat diet plus PFOA, but it had no impact on liver cholesterol concentrations. Serum cholesterol was not monitored. A high-fat diet predisposes animals and possibly humans to hepatic steatosis.

### 4.2 Cancer

#### 4.2.1 Animal Cancer Bioassays

The only animal carcinogenicity studies available for PFOA indicate that exposure can lead to liver adenomas (Biegel et al. 2001), Leydig cell adenomas (Biegel et al. 2001; Butenhoff et al. 2012), and pancreatic acinar cell tumors (PACT) (Biegel et al. 2001) in male Sprague-Dawley rats. In the Butenhoff et al. (2012) study there was an increase in liver carcinomas at the high dose (14.2 mg/kg/day) in the males compared to controls (6% versus 10%). For the females receiving 16.1 mg/kg/day (i.e., the high dose) the tumor incidence compared to controls was 0% versus 2%. The increase in liver tumors did not show a direct relationship to dose in the male rats and was not statistically significantly elevated in either males or females at the high dose when
compared to controls (Butenhoff et al. 2012). Liver adenomas were observed in the Biegel et al. (2001) study at an incidence of 10/76 (13%) at 20 mg/kg/day. The incidence in the control group was 2/80 (3%).

Butenhoff et al. (2012) also observed increased incidence of testicular Leydig cell tumors (LCTs) in rats. At the 1-year sacrifice, testicular masses were found in 7/50 (14%) high-dose and 2/50 (4%) low-dose rats, but not in any of the controls. A significant increase (p < 0.05) in the incidence of testicular (Leydig) cell adenomas was also observed in the high-dose male rats at the end of the study. The LCT incidence in the control, low-, and high-dose groups was 0/50 (0%), 2/50 (4%), and 7/50 (14%), respectively. Biegel et al. (2001) observed a significant increase in the incidence of Leydig cell adenomas in the treated rats (11%, 8/76) when compared to the pair-fed control rats (3%, 2/78) supporting the observations from the Butenhoff et al. (2012) study. The LCTs in the Butenhoff et al. (2012) study were accompanied by statistically significant testicular vascular mineralization and by Leydig cell hyperplasia in the Biegel et al. (2001) study.

PACTs were only observed in the Biegel et al. (2001) study, with an incidence of 11% at 20 mg/kg/day compared to controls. Although no PACTs were observed by Butenhoff et al. (2012), pancreatic acinar hyperplasia was observed at 1.3 and 14.2 mg/kg/day at incidences of 6% and 2%, respectively. Re-examination of the pancreatic lesions in Butenhoff et al. (2012) and Biegel et al. (2001) resulted in the conclusion that the high dose increased the incidence of proliferative acinar cell lesions in both studies. Some lesions in the Biegel et al. (2001) study had progressed to adenomas but not those in the Butenhoff et al. (2012) study.

The initial findings from the Butenhoff et al. (2012) study were equivocal for mammary fibroadenomas in female rats. However, a re-examination of the tissues by a pathology working group (PWG) found no statistically significant differences in the incidence of fibroadenomas or other neoplasms of the mammary gland between control and treated animals (Hardisty et al. 2010). The PWG used the diagnostic criteria and nomenclature of the Society of Toxicological Pathologists for the re-examination.

### 4.2.2 Human Epidemiology Studies

Evidence of carcinogenic effects of PFOA in epidemiology studies is based on studies of kidney and testicular cancer. These cancers have relatively high survival rates (2005–2011 5-year survival rates are 73% and 95%, respectively, for kidney and testicular cancer, based on NCI Surveillance, Epidemiology and End Results data); therefore, studies that examine population cancer incidence are particularly useful for these types of cancers. For testicular cancer, the high-exposure community studies also have the advantage of including the age period of greatest risk, as the median age at diagnosis is 33 years. The two occupational cohorts in Minnesota and West Virginia (most recently updated, respectively, in Raleigh et al. 2014 and Steenland and Woskie, 2012) do not support an increased risk of these cancers, but each of these is limited by a small number of observed cases (six kidney cancer deaths, 16 incident kidney cancer cases, and five incidence testicular cancer cases in Raleigh et al. [2014]; 12 kidney cancer deaths and one testicular cancer death in Steenland and Woskie [2012]). Two studies involving members of the C8 Health Project showed a positive association between PFOA levels (mean at enrolment 0.024 µg/mL) and kidney and testicular cancers (Barry et al. 2013; Vieira et al. 2013);
some of the cases included in these studies overlap. None of the general population studies examined kidney or testicular cancer, but no associations were found in the general population between mean serum PFOA levels up to 0.0866 µg/mL and colorectal, breast, prostate, bladder, and liver cancer (Bonefeld-Jørgensen et al. 2014; Eriksen et al. 2009; Hardell et al. 2014; Innes et al. 2014).

4.2.3 Cancer Mode of Action

The mode of carcinogenic action of PFOA is not clearly understood. Some researchers have concluded from the available data that the liver tumors observed in the cancer bioassays can be attributed mostly to the impact of PFOA on peroxisome proliferation based on a hypothesized lower sensitivity of humans to this MOA (Klaunig et al. 2003, 2012). Some data support the hypothesis that PPARα agonism MOA could be responsible for observed liver tumors in animals. Rosen et al. (2008a, 2008b) examined transcript profiles in the livers of wild-type and PPARα-null mice dosed with PFOA for up to 7 days. This study showed that animal responses were consistent with PPARα agonism, but evidence also shows PPARγ agonism (down-regulation of cholesterol synthesis) and activation of CAR and PXR-related genes (Martin et al. 2007). There is evidence that PFOA is a potent peroxisome proliferator inducing peroxisome formation in the livers of rats and mice (Elcombe et al. 2010; Minata et al. 2010; Pastoor et al. 1987; Wolf et al. 2008; Yang et al. 2001). Beyond activation of PPARα, few studies have evaluated whether additional steps (i.e., cell proliferation and apoptosis) are in the hypothesized PPARα agonism MOA (Elcombe et al. 2010; Minata et al. 2010; Wolf et al. 2008). For example, no studies were identified that focused specifically on preneoplastic foci and clonal expansion of altered cells after PPAR activation.

The proposed MOA for testicular LCTs is linked to decreased serum testosterone levels and signaling of the hypothalamus to produce gonadotropin releasing hormone (GnRH), a signaling agent for the pituitary to release luteinizing hormone which upregulates testosterone production in Leydig cells. Administering PFOA to adult male rats by gavage for 14 days was shown to decrease testosterone levels and increase serum estradiol levels (Cook et al. 1992). These endocrine changes correlated with its potency to induce LCTs in rats and were hypothesized to play a role in the PFOA-induction of LCTs (Biegel et al. 2001). Support for PPARα-mediated inhibition of testosterone production is found in Li et al. (2011). However, some researchers have proposed that data are not currently sufficient to demonstrate that the other key steps in the postulated MOA are present in PFOA-treated animals following exposures that lead to tumor formation (Klaunig et al. 2012).

Two hypothetical MOAs have been proposed for PACTs (Klaunig et al. 2003, 2012; Obourn et al. 1997). In one case, growth factors such as cholecystokinin (CCK) and/or gastrin activate a feedback loop resulting in proliferation of the secretory pancreatic acinar cells leading to tumors. The other proposed MOA suggests that increased serum testosterone supports the growth of acinar cell preneoplastic foci.

Li et al. (2011) found that serum testosterone levels were decreased, not increased, in wild-type, PPARα-null and mice with humanized PPARα. Biegel et al. (2001) found no change in serum testosterone in their bioassay. Obourn et al. (1997) studied the impact of PFOA on CCK and trypsin using in vitro assays and found that PFOA was not an agonist for the cholecystokinin
agonism receptor receptor that activated CCK release. Plummer et al. (2007) reported on gene expression changes induced in pancreatic acinar cells isolated from Sprague-Dawley rats fed diets containing 300 parts per million (~20 mg/kg/day) PFOA for 28 days. Expression of genes regulated by PPARα, γ, δ in pancreatic acinar cells was directly opposite of the expression of those same genes in liver tissue. At the present time, data are insufficient to demonstrate a MOA that can account for the PACTs identified in the chronic study by Biegel et al. (2001).

The mutagenicity data on PFOA are largely negative, although some evidence shows clastogenicity in the presence of microsomal activation and at cytotoxic concentrations (Murli 1996a, 1996b). PFOA’s clastogenic effects are likely the result of an indirect mechanism, given the chemical and physical properties of PFOA (i.e., it is not metabolized, it binds to cellular proteins, and it carries a net negative electrostatic surface charge). PFOA has the potential to interfere with the process of DNA replication because of its protein-binding properties and the fact that histone proteins, spermine, and spermidine carry a net positive surface charge. Involvement of reactive oxygen species (ROS) in the MOA as a result of PFOA alone is unlikely because of its metabolic stability. Conditions leading to ROS would be a function of metabolic responses perturbed by PFOA, rather than PFOA alone.

A compound that is not metabolized will not be able to covalently alter the structure of DNA or intercalate because of electrostatic repulsion between the aromatic base pi bond electrons and the partial negative charges on the PFOA fluoride atoms. Because of its protein-binding properties, PFOA could affect one or more of the proteins involved in the process of DNA replication or cell division (cytoskeletal proteins), however, no mechanistic studies were identified that examined the biochemical effects of PFOA on DNA replication or cell division. No data support this as a MOA for clastogenic effects.

4.2.4 Weight of Evidence Classification

Under EPA’s Guidelines for Carcinogen Risk Assessment (USEPA 2005) there is Suggestive Evidence of Carcinogenic Potential of PFOA in humans. The bioassay findings for Leydig cell testicular tumors in rats, combined with the C-8 Panel finding of a probable link to testicular and renal tumors among the members of the C8 Health Project, support this conclusion.

In June 2014, 20 experts met at the International Agency for Research on Cancer (IARC) in Lyon, France, to assess the carcinogenicity of perfluorooctanoic acid (PFOA), among other chemicals. Although the assessments have not yet been published (they are expected to be published in volume 110 of the IARC monographs), the expert findings from this meeting are available in a peer-reviewed publication (Benbrahim-Tallaa et al. 2014), and their determination is on the IARC website. The working group classified PFOA as possibly carcinogenic to humans (Group 2B) and considered the evidence regarding mechanisms of PFOA-associated carcinogenesis to be moderate. This assessment did not lead to a change in the overall classification of PFOA by IARC.
5.0 DOSE-RESPONSE ASSESSMENT

As an initial step in the dose-response assessment, EPA identified a suite of animal studies with NOAELs and/or LOAELs that identified them as potential candidates for development of the RfD for PFOA. These studies included short-term, subchronic, and chronic exposures, including developmental and reproductive toxicity studies. The available studies evaluated endpoints including liver effects (weight changes with histopathology), body weight changes in adults and offspring, reproductive outcomes such as fertility, developmental effects (altered puberty, survival, and developmental delays such as eye opening), and immune effects. The candidate studies were selected based on their NOAEL and/or LOAEL values, a duration of 11 to 91 days, use of a control, and two or more doses. From these studies, those that presented serum data amenable for modeling (i.e., determination of HEDs) were selected for dose-response analysis. The subset of studies amenable for use in deriving HED based on average serum measurements from the pharmacokinetic model is limited because of the need to have dose and species-specific serum values for model input as well as exposure durations of sufficient length to achieve values near to steady-state projections or applicable to developmental endpoints with lifetime consequences following short-term exposures. The pharmacokinetically modeled average serum values from the animal studies are restricted to the animal species selected for their low dose response to oral PFOA intakes.

As described in section 3.2.4, EPA used the Wambaugh et al. (2013) pharmacokinetic model to derive the average serum concentrations associated with the candidate NOAELs and LOAELs from the toxicological database. Studies with serum information for each of the doses that demonstrated dose response and were amendable for modeling of the area under the curve (AUC) at the time of sacrifice were used. The AUC results were converted to average serum values at the time of sacrifice with consideration of the duration of exposure. The average serum values were converted to the HED, as described further below.

The data were analyzed within a Bayesian framework using a Markov Chain Monte Carlo sampler implemented as an R statistical analysis package developed by EPA to allow predictions across species, strains, and genders, and to identify serum levels associated with the external doses at the NOAEL and LOAEL. The model predictions were evaluated by comparing each predicted final serum concentration to the serum value measured in the supporting animal studies.

The average serum concentrations were converted into an oral equivalent dose by recognizing that clearance from the body equals dose to the body. Clearance can be calculated if the rate of elimination (derived from half-life) and the volume of distribution are both known. EPA used the Bartell et al. (2010) calculated human half-life of 2.3 years (general population) with the Thompson et al. (2010) volume of distribution ($V_d$) of 0.17 L/kg body weight (bw) to determine a clearance of $1.4 \times 10^{-4}$ L/kg bw/day by the following equation:

$$CL = V_d \times (\ln 2 \div t_{1/2}) = 0.17 \text{ L/kg bw} \times (0.693 \div 839.5 \text{ days}) = 0.00014 \text{ L/kg bw/day}$$

Where:

$V_d = 0.17 \text{ L/kg}$

$\ln 2 = 0.693$

$t_{1/2} = 839.5 \text{ days (2.3 years x 365 days/year = 839.5 days)}$
Multiplying the derived average serum concentrations (in µg/mL) for the NOAELs and LOAELs identified in the key animal studies by the clearance value predicts oral HEDs in mg/kg bw/day for each corresponding serum measurement. The HED values are the predicted human oral exposures necessary to achieve serum concentrations equivalent to the NOAEL or LOAEL in the animal toxicity studies using linear human kinetic information.

Table 5-1 provides the NOAEL, LOAEL, and effect information from those studies, along with the associated average serum values and the percent of steady state represented by the LOAEL.

### Table 5-1. Human Equivalent Doses Derived from the Modeled Animal Average Serum Values

<table>
<thead>
<tr>
<th>Study</th>
<th>Dosing duration days</th>
<th>NOAEL mg/kg/d</th>
<th>NOAEL Av serum mg/L</th>
<th>HED mg/kg/d</th>
<th>LOAEL mg/kg/d</th>
<th>LOAEL (Av serum) mg/L</th>
<th>HED mg/kg/d</th>
</tr>
</thead>
<tbody>
<tr>
<td>DeWitt et al. (2008): mice; ↓ IgM response to SRBC</td>
<td>15</td>
<td>1.88</td>
<td>38.2</td>
<td>0.0053</td>
<td>3.75</td>
<td>61.9</td>
<td>0.0087</td>
</tr>
<tr>
<td>Lau et al. (2006): mice decreased ↓ pup ossification (m, f), accelerated male puberty</td>
<td>17</td>
<td>None</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>38.0</td>
<td>0.0053</td>
</tr>
<tr>
<td>Palazzolo et al. (1993); Perkins et al. (2004): rats; ↑liver weight/necrosis</td>
<td>91</td>
<td>0.64</td>
<td>31.6</td>
<td>0.0044</td>
<td>1.94</td>
<td>77.4</td>
<td>0.0108</td>
</tr>
<tr>
<td>Wolf et al. (2007): mice; GD 1–17 ↓ Pup body weight</td>
<td>17</td>
<td>None</td>
<td>-</td>
<td>-</td>
<td>3</td>
<td>77.9</td>
<td>0.0109</td>
</tr>
<tr>
<td>Wolf et al. (2007): mice; GD 7–17 ↓ Pup body weight</td>
<td>11</td>
<td>None</td>
<td>-</td>
<td>-</td>
<td>5</td>
<td>87.9</td>
<td>0.0123</td>
</tr>
<tr>
<td>Butenhoff et al. (2004a): ↓ relative body weight/↑ relative kidney weight and ↑kidney: brain weight ratio in F0 and F1 at sacrifice</td>
<td>84</td>
<td>None</td>
<td>-</td>
<td>-</td>
<td>1</td>
<td>45.9</td>
<td>0.0064</td>
</tr>
</tbody>
</table>

Notes:
Significance p < 0.05 or p < 0.01
m = male; f = female; SRBC = sheep red blood cell; IgM = immunoglobulin M; GD = gestation day

The external doses in each of the studies varied. The NOAELs ranged from 0.64 to 1.88 mg/kg/day. The corresponding average serum values ranged from 1.6 mg/L (rat) to 38.2 mg/L (mouse). At the LOAEL, the average serum values range from 38 µg/mL (mouse) to 87.6 µg/mL (monkey) at doses estimated to represent about 56% to 96% of steady state. At the low end of the range the effects of concern are observed in neonates (low birth weight, delays in developmental endpoints, with increased kidney weight at sacrifice later in life).
Much of the variability in the average serum levels for the LOAELs was due to differences in the doses used in the individual studies. For example, two of the modeled endpoints (Wolf et al. 2007) identified low birth weights in mouse pups as the critical effect, but had a single external dose that was 3 to 5 times higher than the low dose from the Lau et al. (2006) mouse study (1 mg/kg/day).

Among the studies conducted in mice, dose was a more important variable in determining serum level and percent of steady state than duration of exposure. This is a characteristic of the nonlinear toxicokinetics exhibited by PFOA. The half-life for doses that exceed the resorption capacity of the kidney are shorter than lower doses that can be resorbed and thereby persist in serum over a longer exposure duration. For example, in Wolf et al. (2007), an 11-day dose of 5 mg/kg/day resulted in an average serum of 88 mg/L (82% of concentration at steady state or Css) whereas a 1 mg/kg/day dose for 17 days resulted in an average serum of 38 mg/L (56% ofCss). In rats, dosed at 1 mg/kg/day, over two generations (84 days), an average serum of 45.9 mg/L at 87% of steady state was determined (Butenhoff et al. 2004a). A 91-day exposure (Palazzolo et al. 1993/Perkins et al. 2004) to 1.94 mg/kg/day resulted in a serum value of 77 mg/kg/day and was 91% of steady state. The endpoints in Butenhoff et al. (2004a) are effects on body weight and relative kidney weight in the adult F0 and F1 rats, while the endpoint for Palazzolo et al. (1993)/Perkins et al. (2004) was systemic increased liver weight with lower-level necrosis.

Assuming that MOA and susceptibility to toxicity do not vary and that pharmacokinetics alone explains variation, it is reasonable to expect similar concentrations to cause similar effects in humans and are more important than both dose and duration once steady state is attained.

5.1 Uncertainty Factors

An uncertainty factor for intraspecies variability (UF$_H$) of 10 is assigned to account for variability in the responses within the human populations because of both intrinsic (toxicokinetic genetic, life stage, health status) and extrinsic (life style) factors that can influence the response to dose. No information was available relative to variability in the human population that supports a factor other than 10.

An uncertainty factor for interspecies variability (UF$_A$) of 3 is applied to account for uncertainty in extrapolating from laboratory animals to humans (i.e., interspecies variability). The 3-fold factor is applied to account for toxicodynamic differences between the animals and humans. The HEDs were derived using average serum values from a model to account for toxicokinetic differences between animals and humans.

An uncertainty factor for LOAEL to NOAEL extrapolation (UF$_E$) of 10 is applied to all PODs other than the Palazzolo et al. (1993)/Perkins et al. (2004) and DeWitt et al. (2008) studies to account for use of a LOAEL for the POD. The POD for the Palazzolo et al. (1993)/Perkins et al. (2004) and DeWitt et al. (2008) studies are NOAELs for the effect identified as critical.

An uncertainty factor for extrapolation from a subchronic to a chronic exposure duration (UF$_S$) of 1 is applied because the PODs are based on average serum concentrations and determined to represent >80% of steady state for each study (81–91%), except for the Lau et al. (2006) developmental study (56%). The Lau et al. (2006) developmental HED was not adjusted.
for lifetime exposures because the average serum values associated with the developmental studies are more protective than those for the longer-term studies of systemic toxicity. A UF of 10 was applied to the DeWitt et al. (2008) study serum derived HED reflecting (74%) of steady state because the data suggest that longer term exposures to the same dose have the potential to increase serum values beyond the levels indicated by the 15-day study. In addition, the NOAEL for immunological effects (0.94 mg/kg/day) was a LOAEL for effects on liver weight in the absence of histological evaluation on both days 16 and 31 following a 15-day exposure (DeWitt et al. 2008). Thus, there is a potential that lifetime exposures at steady state can affect the liver and increase the risk for tissue damage.

A database uncertainty factor (UFD) of 1 was applied to account for deficiencies in the database for PFOA. There are extensive human data from epidemiological data from the general population as well as worker cohorts. The epidemiology data provide strong support for the identification of hazards observed following exposure to PFOA in the laboratory animal studies and human relevance. However, uncertainties in the use of the available epidemiology data precluded their use at this time in the quantification of the effect level for derivation of the drinking water HA. In animals, acute, short term, subchronic and chronic studies, including a long term cancer study, are available. In addition, several developmental studies and a two-generation reproductive toxicity study evaluating exposure of pregnant dams and offspring to PFOA are available.

5.2 RfD Determination

Table 5-2 provides the calculations for candidate RfDs using the HEDs derived from the NOAEL or LOAEL average serum concentrations using pharmacokinetic modeling based on the serum values measures collected at animal sacrifice. Uncertainty factors (see section 5.1) were applied to each POD, and Table 5-2 illustrates the array of candidate RfD outcomes. Each POD is affected by the doses used in the subject study, the endpoints monitored, and the animal species/gender studied. Thus, the array of outcomes, combined with knowledge of the individual study characteristics helps to inform selection of an RfD that will be protective for humans. Other than DeWitt et al. (2008) and Lau et al. (2006), all of the selected studies had serum levels that had reached > 80% of Css. It is important to note the relatively narrow range of RfDs across the multiple endpoints and study durations evaluated.

Using the pharmacokinetic model of Wambaugh et al. (2013), average serum PFOA concentrations were derived from AUC considering the number of days of exposure before sacrifice. The predicted serum concentrations were converted as described above to oral HEDs mg/kg/day for each corresponding serum measurement. The candidate RfDs in Table 5-2 range from 0.00002 to 0.00015 mg/kg/day across multiple endpoints. The RfD of 0.00002 mg/kg/day calculated from HED average serum values from Lau et al. (2006) was selected. This RfD is derived from reduced ossification of the proximal phalanges (forelimb and hindlimb) and accelerated puberty in male pups (4 days earlier than controls) as the critical effects. The POD for the derivation of the RfD for PFOA is the HED of 0.0053 mg/kg/day that corresponds to a LOAEL that represents approximately 60% of steady-state concentration. An UF of 300 (10 UFH, 3 UF<sub>Λ</sub>, and 10 UF<sub>L</sub>) was applied to the HED LOAEL to derive an RfD of 0.00002 mg/kg/day.
<table>
<thead>
<tr>
<th>POD</th>
<th>HED POD mg/kg/day</th>
<th>UFH</th>
<th>UFΑ</th>
<th>UF1</th>
<th>UF5</th>
<th>UFD</th>
<th>UFtotal</th>
<th>Candidate RfD mg/kg/day</th>
</tr>
</thead>
<tbody>
<tr>
<td>PK-HEDNOAEL, Palazzolo et al. (1993)/Perkins et al. (2004) rats; ↑ liver weight/necrosis</td>
<td>0.0044</td>
<td>10</td>
<td>3</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>30</td>
<td>0.00015</td>
</tr>
<tr>
<td>PK-HEDLOAEL, Wolf et al. (2007) GD1-17 mice; ↓ Pup body weight</td>
<td>0.0109</td>
<td>10</td>
<td>3</td>
<td>10</td>
<td>-</td>
<td>-</td>
<td>300</td>
<td>0.00004</td>
</tr>
<tr>
<td>PK-HEDLOAEL, Wolf et al. (2007) GD 7-17 mice; ↓ Pup body weight (serum from pups on PND 22)</td>
<td>0.0123</td>
<td>10</td>
<td>3</td>
<td>10</td>
<td>-</td>
<td>-</td>
<td>300</td>
<td>0.00004</td>
</tr>
<tr>
<td>PK-HEDNOAEL, DeWitt et al. (2008) mice; ↓ IgM response to SRBC</td>
<td>0.0053</td>
<td>10</td>
<td>3</td>
<td>-</td>
<td>10</td>
<td>-</td>
<td>300</td>
<td>0.00002</td>
</tr>
<tr>
<td>PK-HEDLOAEL, Lau et al. (2006) mice decreased ↓ pup ossification (m, f), accelerated male puberty</td>
<td>0.0053</td>
<td>10</td>
<td>3</td>
<td>10</td>
<td>-</td>
<td>-</td>
<td>300</td>
<td>0.00002</td>
</tr>
<tr>
<td>PK-HEDLOAEL, Butenhoff et al. (2004a) ↓ relative body weight/↑ relative kidney weight and ↑ kidney: brain weight ratio in F0 and F1 at sacrifice</td>
<td>0.0064</td>
<td>10</td>
<td>3</td>
<td>10</td>
<td>-</td>
<td>-</td>
<td>300</td>
<td>0.00002</td>
</tr>
</tbody>
</table>

Notes:
PK-HED = pharmacokinetic human equivalent dose; NOAEL = no observed adverse effect level; LOAEL = lowest observed adverse effect level; GD = gestation day; IgM = immunoglobulin M; m = male; f = female; SRBC = sheep red blood cell; UFH = intraindividual uncertainty factor; UFα = interspecies uncertainty factor; UF5 = subchronic to chronic uncertainty factor; UF1 = LOAEL to NOAEL uncertainty factor; UF0 = incomplete database uncertainty factor; UFtotal = total (multiplied) uncertainty factor

Decreased pup body weights also were observed in studies conducted by Wolf et al. (2007), White et al. (2009), and Lu et al. (2015) using mice receiving external doses within the same order of magnitude (1, 3, and 5 mg/kg/day respectively) as those chosen for the RfD. The selected RfD from the reproductive and developmental studies is supported by the longer term RfD for effects on the response of the immune system to external challenges as observed following the short-term exposures to mature mice and the effects on kidney weight observed at the time of sacrifice in the F0 and F1 adult males that provided the serum in the Butenhoff et al. (2004a) study (DeWitt et al. 2008).

Support for the selected RfD also is provided by other key studies with NOAELs and LOAELs similar to those used for quantification, but lacking serum data that could be used for modeling. There were effects on liver weight and hepatic hypertrophy in the Perkins et al. (2004) and DeWitt et al. (2008) studies that were modeled but not considered in the derivation of the
RfD because of a lack of data to demonstrate adversity as determined by the Hall et al. (2012) criteria at the dose causing the liver effects but not the effects identified as critical. The LOAEL for evidence of hepatic necrosis and other signs of tissue damage in the F1 male rat pups from the Butenhoff et al. (2004a) study was 3 mg/kg/day; the NOAEL was 1 mg/kg/day. In the Loveless et al. (2008) study, the LOAEL for increased relative liver weight accompanied by focal liver necrosis in male rats was 10 mg/kg/day and the NOAEL was 1 mg/kg/day, while in male mice, the LOAEL for the same effect was 1 mg/kg/day and the NOAEL was 0.3 mg/kg/day following a 29-day exposure. In the study by Tan et al. (2013), the degree of damage to the liver at 5 mg/kg/day became more severe with increased necrosis, inflammation, and steatosis when animals were given a high-fat diet. The HED modeled from the average serum value in mice for the LOAEL (3 mg/L) from Wolf et al. (2007) and White et al. (2009) was 0.0110 mg/kg/day, about twice that for the rats in the Lau et al. (2006) study (0.0053 mg/kg/day). Both studies lacked a NOAEL. Each of these data sets support LOAELs for the critical study by Lau et al. (2006) selected for RfD derivation and, as a consequence, the HED derived from modeled average serum values.

6.0 HEALTH ADVISORY VALUES

6.1 Relative Source Contribution

As described in section 2.2 and below, humans can be exposed to PFOA and precursor chemicals via multiple sources, including air, food, and consumer and industrial products (including textiles and rugs). The most common route of exposure to PFOA is via the diet, followed by indoor dust, especially for children.

Food is a significant source of exposure to PFOA: It has been detected in a variety of foods including snack foods, vegetables, meat, dairy products, human breast milk, and fish. Occurrence in food products can result from the use of contaminated water in processing and preparation; growth of food in contaminated soils; direct and indirect exposures of domestic animals to PFOA from drinking water, consumption of plants grown in contaminated soil, and through particulate matter in air; fish from contaminated water ways; and packaging materials.

PFOA has been detected in finished drinking water samples collected by EPA and others. PFOA is not regulated under the SDWA and was included in EPA’s UCMR 3. PFOA was detected at a small number of PWSs (0.9%) through this monitoring program. Therefore, there is potential exposure to PFOA from drinking water ingestion.

The vapor pressure of PFOA indicates that volatilization is low; however, PFOA can be released into the atmosphere from industrial and municipal waste incinerators and adsorb to airborne particulates. It can be transported long distances through the atmosphere and has been detected globally at low concentrations. Inhalation of PFOA is possible, and it has been measured in indoor air in residential, commercial, and office settings because of its use in carpets, textiles, paint, furniture, and other consumer products. Both air and dust can be a vehicle for volatile telomer alcohols that metabolically degrade to PFOA. Given the widespread commercial and industrial use of PFOA and its physical properties, air is a potential source of exposure to it and the C8:2 telomer alcohol precursors.
PFOA also has been detected in soils and dust from carpets and upholstered furniture in homes, offices, and vehicles. Incidental exposure from soils and dust is an important exposure route, particularly for small children because of their hand-to-mouth behaviors. Also, the levels in soils and surface waters can affect the concentrations in local produce, meat/poultry, dairy products, fish, and particulates in the air.

In summary, based on the physical properties and available exposure information for PFOA, there are many are potential sources. Following EPA’s Exposure Decision Tree in its 2000 methodology (USEPA 2000), significant potential sources other than drinking water ingestion exist; however, information is not available to quantitatively characterize exposure from all of these different sources (Box 8B in the Decision Tree). Therefore, EPA recommends an RSC of 20% (0.20) for PFOA.

6.2 Lifetime Health Advisory

Based on the consistency of the responses across the chronic studies and those for reproductive and developmental endpoints, and with recognition of the use of developmental toxicity as the most sensitive endpoint, 0.00002 mg/kg/day was selected as the RfD for PFOA. This value is based on the HED for developmental effects (reduced ossification in male and female pups and accelerated puberty in male pups) from the Lau et al. (2006) study. The RfD that serves as the POD for the lifetime HA is applicable for effects other than those occurring during development. The candidate RfD values derived from the two-generation study by Butenhoff et al. (2004a) for effects on adult body weight plus relative liver and kidney weights in F0 and F1 male rats is the same as the value based on the developmental effects observed by Lau et al (2006). The candidate RfD from the DeWitt et al. (2008) study for suppression of the immunological response to a challenge is the same as that from Lau et al. (2006).

Due to the potential increased susceptibility during the time period of pregnancy and lactation, EPA used drinking water intake and body weight parameters for lactating women in the calculation of a lifetime HA for this target population during this potential critical time period. EPA used the rate of 54 mL/kg-day representing the consumers only estimate of combined direct and indirect community water ingestion at the 90th percentile for lactating women (see Table 3-81 in USEPA 2011b). Comparing the pregnant woman and the lactating woman, the lactating woman is the more protective scenario given her increased water intake rate for her body weight needed to support milk production. Additionally, human studies demonstrate that PFOA is transferred from mother to infant via cord blood and breast milk. A recent study showed that breast milk contributed > 83% of the PFOA exposure in 6-month-old infants (Haug et al. 2011).

The exposure factors applied to the RfD to derive the lifetime HA are specific to the most sensitive population and will be protective of pregnant women as well as of the general population. Thus, the protection conferred by the lifetime HA is broadly protective of public health.

The lifetime HA for PFOA is calculated as follows:

A DWEL is derived from the RfD and assumes that 100% of the exposure comes from drinking water.
\[
\text{DWEL} = \frac{\text{RfD} \times \text{bw}}{\text{DWI}}
\]

\[
\text{DWEL} = 0.00002 \text{ mg/kg/day} = 0.00037 \text{ mg/L}
\]

\[
= \frac{0.054 \text{ L/kg-day}}{0.054 \text{ L/kg-day}} = 0.00007 \text{ mg/L (rounded to 0.00007 mg/L)}
\]

The lifetime HA is calculated after application of a 20% RSC (see section 6.1) as follows:

\[
\text{Lifetime HA} = \text{DWEL} \times \text{RSC}
\]

\[
= 0.00007 \text{ mg/L} \times 0.2
\]

\[
= 0.00007 \text{ mg/L (rounded to 0.00007 mg/L)} = 0.07 \mu\text{g/L}
\]

The lifetime HA for PFOA is based on effects (reduced ossification in male and female pups and accelerated puberty in male pups) on the developing fetus resulting from exposures that occur during gestation and lactation. These developmental endpoints are the most protective for the population at large and are effects that can carry lifetime consequences for a less than lifetime exposure. Developmental toxicity endpoints (following less than chronic exposures during a defined period of gestation or lactation) can be analyzed in both acute and chronic exposure scenarios. Because the developing organism is changing rapidly and is vulnerable at various stages in development, a single exposure at a critical time in development can produce an adverse effect (USEPA 1991). Additionally, PFOA is extremely persistent in both the human body and the environment; thus, even a short-term exposure results in a body burden that persists for years and can increase with additional exposures.

Because the critical effect identified for PFOA is a developmental endpoint and can potentially result from a short-term exposure during a critical period of development, EPA concludes that the lifetime HA for PFOA is applicable to both short-term and chronic risk assessment scenarios. Thus, the lifetime HA of 0.07 μg/L also applies to short-term exposure scenarios (weeks to months) to PFOA in drinking water, including during pregnancy and lactation.

Adverse effects observed following exposures to PFOA and PFOS are the same or similar and include effects on serum lipids, birth weight, and serum antibodies in humans. Among the animal studies, there are common effects on the liver, neonate development, and responses to immunological challenges. Both compounds also were associated with tumors in long-term animal studies. The effects that serve as the basis for the RfDs for both PFOA and PFOS are developmental endpoints (reduced ossification and accelerated puberty in males for PFOA and decreased pup birth weight for PFOS (USEPA 2016a, 2016b). Because the RfDs for both PFOA
and PFOS are based on similar developmental effects and are numerically identical, where these two chemicals co-occur at the same time and location in a drinking water source, a conservative and health protective approach that EPA recommends would be to compare the sum of the concentrations ([PFOA] + [PFOS]) to the HA (0.07 μg/L).

7.0 QUANTIFICATION OF CANCER RISK

The evidence for the carcinogenicity of PFOA is considered suggestive because only one species has been evaluated, and the tumor responses (liver, testicular Leydig cell, and pancreatic acinar cell tumors) occurred primarily in males. Dose-response data are only available for the LCTs in one study. The dose-response data on LCTs from the (Butenhoff et al. (2012) studies were modeled to provide a perspective on the magnitude of the potential cancer risk as it compares with the level of protection provided by the RfD.

Under EPA’s Guidelines for Carcinogen Risk Assessment (USEPA 2005), when there is Suggestive Evidence for Carcinogenic Potential for a chemical, a dose-response assessment would generally not be attempted. The guidelines state that, when the evidence includes a well-conducted study, quantitative analyses could be useful for some purposes—for example, by providing a sense of the magnitude and uncertainty of potential risks, ranking potential hazards, or setting research priorities. The data from the Butenhoff et al. (2012) study are adequate to support a quantitative cancer dose-response assessment for PFOA’s testicular tumors. The epidemiology studies demonstrate an association of serum PFOA with kidney and testicular tumors among highly exposed members of the general population. Thus, EPA concluded that a quantitative analysis could be useful by providing a sense of the magnitude of potential carcinogenic risk.

The dose-response data for LCTs in rats was analyzed using the multistage cancer model for a dichotomous data set to predict the dose at which a 4% increase in tumor incidence would occur (see appendix A). A benchmark response of 4% was chosen as the low end of the observed response range within the study results. The resulting benchmark dose level (BMDL01) was 1.99 mg/kg/day, which yields a HED of 0.58 mg/kg/day and a slope factor of 0.07 (mg/kg/day)^{-1}. The cancer slope factor was calculated to determine if a lifetime HA derived from the RfD would be protective for the cancer endpoint. As a comparative analysis, the concentration of PFOA in drinking water that would have a one-in-1-million chance of an increased cancer risk was calculated using the oral slope factor for testicular tumors, assuming a default adult body weight of 80 kg (mean weight for adults ages 21 and older) (Table 8.1 in USEPA 2011b) and a default drinking water intake rate of 2.5 L/day (consumers only estimate of combined direct and indirect community water ingestion at the 90th percentile for adults ages 21 and older) (Table 3-33 in USEPA 2011b). The resultant 0.5 μg/L value is greater than the lifetime HA (0.07 μg/L) based on noncancer effects (see section 6.22.2.), indicating that the HA derived based on the developmental endpoint is protective for the cancer endpoint.

\[ 10^{-6} \text{ cancer risk} = \frac{0.000001 \times 80 \text{ kg}}{0.07 \text{ mg/kg/day} \times 2.5 \text{L/d}} = 0.00046 \text{ mg/L} \text{ rounded to 0.5 μg/L} \]
8.0 EFFECTS CHARACTERIZATION

8.1 Uncertainty and Variability

The variability and uncertainty in the lifetime HA is a function of both intrinsic and extrinsic factors. EPA’s HESD for PFOA identified 20 short- or long-term studies that provided dose-response information and were considered during the quantitative assessment of risk (USEPA 2016a). The range of external dose NOAELs among the 20 studies is 0–30 mg/kg/day for females and 7.5 mg/kg/day for males. The LOAELs range from zero to 30 mg/kg/day for females and zero to 14.2 mg/kg/day for males (USEPA 2016a). Six dose-response data sets included the serum data necessary for modeling to derive HEDs for use as the POD for the RfD. Average serum values from those studies were chosen for use in the derivation of the RfD. The external dose range for the NOAELs in the modeled studies is 0–1.88 mg/kg/day and the LOAEL range is 1–5 mg/kg/day (USEPA 2016a). EPA believes the uncertainty in the chosen POD and the reliance on studies with serum data is minimized because of the large and extensive database examining the PFOA hazard and the selection of reduced ossification, and accelerated male puberty as the critical effects with lifetime implications at a LOAEL dose (1 mg/kg/day) from the low end of the narrow range of values evaluated.

The intrinsic uncertainties in the risk assessment reflect the fact that the NOAELs and LOAELs are derived using central tendency estimates for variables such as body weight, food and drinking water intakes, and dose. The central tendency estimates are derived from small numbers of genetically, relatively similar animals representing one or more strains of rats or mice living in controlled environments. The animals lack the heterogeneous genetic complexity, behavioral diversity, and complex habitats experienced by humans. These differences, to some extent, are minimized through the use of the modeled central tendency outcomes and their standard deviations to help inform the application of the uncertainty factors.

Variability in the study outcomes is extrinsically a function of study design and the endpoints monitored. Studies of systemic toxicity monitor an array of endpoints that are not evaluated in studies of reproductive, developmental, neurological, and immunological toxicity. The reverse is true for the other types of toxicity studies compared to standard short-term to long-term systemic studies. Studies of systemic toxicity do not often examine neurological or immunological endpoints. Increases in liver weight were seen in many of the studies with dose-response information but only a few of the studies carried out a histological evaluation of the liver to support a determination of whether the increase in liver weight could be classified as adverse according to the Hall et al. (2012) criteria.

The RfD is based on the HED derived from serum levels at the LOAEL from developmental study in mice with application of an uncertainty factor of 300 to cover extrapolation from a LOAEL to a NOAEL, variability in the human population, and differences in the ways humans and rodents respond to the PFOA that reaches their tissues (Lau et al. 2006). The selected RfD is based on the developmental effects in neonates to provide protection to both the sensitive life stages and the general population. The RfD is supported by the outcomes from two other studies based on different endpoints, Butenhoff et al. (2004a) and DeWitt et al. (2008), with RfDs for systemic effects on liver, kidney and the immune system. These data increase the confidence in the RfD.
8.2 Use of Human Epidemiology Data

The human epidemiology studies provide evidence of an association between PFOA exposure and health effects in humans, and is another line of evidence supporting this assessment. The human data demonstrate an association between PFOA exposure and endpoints, including effects on serum lipids, antibody responses, fetal growth and development, and the liver. They provide support for identification of hazards of PFOA exposure. The associations observed for serum lipids, and reproductive parameters and immunotoxicity are the strongest. For many endpoints, however, the results are inconsistent. Although the human studies collectively support the conclusion that PFOA exposure is a hazard, EPA concluded that, based on several uncertainties associated with the database, the human studies are adequate for use qualitatively in the identification hazard at this time. These considerations are discussed below.

Although mean serum values are presented in the human studies, actual estimates of exposure (i.e., doses/duration) are not available. Thus, the serum level at which the effects were first manifest and whether the serum had achieved steady state or was in decline at the point the effect was evaluated cannot be determined. The NHANES and C8 study data indicate that serum levels in the general population are declining. Because epidemiology data are a reflection of the serum concentration at the time the sample was collected, there is no way to determine if levels were previously higher and had decreased. All of the C8 study serum samples were collected after the PFOA peak exposures had presumably passed. The half-life measurement for the general population of the Little Hocking area was derived from declining serum concentrations over time, demonstrating that serum levels among that population were not constant (Bartell et al. 2010).

Some of the human exposure that results in serum PFOA can come from telomer alcohol PFOA derivatives that break down metabolically to PFOA (Gebbink et al. 2015; Jogsten et al. 2012). The derivatives do not originate from PFOA in drinking water; they usually originate from diet and materials used in the home. Thus, there is added uncertainty in the observed epidemiological associations between serum PFOA and health effects.

Although the epidemiology studies provide valuable associations between exposure to PFOA and the effects seen in animal studies, most of the subjects of the epidemiology studies had other perfluorinated carboxylates and sulfonates and/or other biopersistent contaminants in their blood. Although the study designs adjust for other potential toxicants as confounding factors, their presence constitutes a level of uncertainty that is usually absent in the animal studies.

The database for PFOA includes extensive human data from epidemiology studies of the general population as well as worker cohorts. Data from oral short-term, subchronic, chronic (including evaluation of cancer), reproductive, and developmental studies in laboratory animals also are available. Many of the effects observed in the human epidemiology studies are similar to those seen in the animal studies.

8.3 Consideration of Immunotoxicity

Both human and animal studies have demonstrated the potential effect of PFOA on the immune system. However, there are uncertainties related to MOA and the level, duration, and/or...
timing of exposure that are not yet clearly delineated. As a result, EPA used the animal data rather than the human data to quantify the dose response for immunotoxicity for PFOA.

Taken together, available human studies do not provide consistent evidence of a significant association between PFOA exposure and serological vaccine responses in general (Grandjean et al. 2012; Granum et al. 2013; Looker et al. 2014). Within each study, most estimated associations were statistically nonsignificant, and results were inconsistent by vaccine type and by outcome classification. Authors provided no a priori biological hypothesis to explain why PFOA exposure would impair the antibody response to one vaccine type but not another. Some authors suggested that their results could be explained by different immunostimulatory effects of different vaccines, but they did not elaborate on this hypothesis or provide supporting mechanistic evidence.

One issue related to use of immune biomarkers and antibody levels in human studies is whether small but statistically significant changes in these endpoints, when analyzed on a continuous scale, are clinically meaningful, particularly when most or all subjects are within the normal range. For PFOA, some epidemiology studies attempted to address this issue by analyzing outcomes dichotomized relative to standard reference values, with the implication that values outside the reference range indicate immune abnormalities (Emmett et al. 2006; Grandjean et al. 2012; Looker et al. 2014). A limitation of this approach is that a reference range is typically determined based on the mean plus or minus two standard deviations calculated from a group of healthy adults or children. By definition, 5% of the normal population falls outside of such a reference range (AACC 2015, cited in Chang et al. 2016). The only way to determine whether a given value outside a reference range is truly abnormal is to associate it with a clinical abnormality; this has not been done in most epidemiology studies of immune biomarkers.

Although Grandjean et al. (2012) found fairly consistent, albeit mostly statistically nonsignificant, intrastudy associations between childhood serum PFOA levels and poorer antibody responses against tetanus and diphtheria toxoids, associations with maternal prenatal serum PFOA and PFOS levels were inconsistent between vaccine types. Two studies were strengthened by their measurement of PFOA levels prior to ascertaining vaccine response (Grandjean et al. 2012; Granum et al. 2013), and one had the additional advantage of collecting exposure and outcome information at two time points each (Grandjean et al. 2012). However, the variability in findings by timing of exposure and outcome measurement in the latter study (e.g., mostly nonsignificant associations with prenatal PFOA concentrations, but several significant associations between higher PFOA concentrations at age 5 years and poorer vaccine response at age 7 years) makes the results difficult to interpret. This pattern of results could reflect a window of susceptibility in early childhood, but such an explanation remains conjectural.

None of the studies demonstrated a clinically recognizable increased risk of infectious diseases as a consequence of a diminished vaccine response. Overall, although these results are not sufficient to establish a causal effect of PFOA exposure on an impaired serological vaccine response, some of the positive associations are striking in magnitude and require replication in independent studies.

Chang et al. (2016) recently completed and published a systematic review of 24 epidemiology studies that reviewed a variety of endpoints among the general population,
occupationally exposed workers, children, and adults and concluded that the available epidemiologic evidence is insufficient to reach a conclusion about a causal relationship between exposure to PFOA and PFOS and any immune-related, health condition in humans. The majority of the studies reviewed by the authors are included in EPA’s HESDs for PFOA and PFOS (USEPA 2016a, 2016b). The authors identified numerous weaknesses in study designs, including lack of validation of self-reported medical conditions, basing conclusions on significant associations without considering statistical significance, inadequate consideration of confounding factors, bias, and the role of chance being responsible for outcomes. After application of the Hill et al. (1965) criteria, they faulted the studies for “generally weak associations, no specific endpoints with consistent findings across all relevant studies, uncertainty about any critical duration of exposure and window(s) of susceptibility, mixed exposure-response trends, and a dearth of supportive animal and mechanistic data.”

There remains a need for additional research on MOA, key biomarkers that are reliable indicators for the upstream effects elicited by the PFASs, the temporal relationship between exposure and outcome, plus the analytical and functional impact of PFASs binding to serum immunoglobins and/or related proteins.

### 8.4 Effects on Mammary Gland Development

Several studies in mice have examined postnatal mammary gland development in female mice. A qualitative/quantitative assessment found delayed mammary gland development of female CD-1 mouse pups following maternal doses ≥ 0.01 mg PFOA/kg in Macon et al. (2011) and Tucker et al. (2015). Macon et al. (2011) also found significant differences from controls in quantitative measures of longitudinal and lateral growth and numbers of terminal end buds at 1 mg/kg/day. However, Albrecht et al. (2013) found no significant differences in the average length of mammary gland ducts and the average number of terminal end buds per mammary gland per litter in female pups of PPARα wild type, PPARα-null, or hPPARα sv/129 following a maternal dose of 3 mg/kg using an approach to scoring that lacked a qualitative component adjustment such as that used by Macon et al. (2011) in identifying the 0.01 mg/kg/day dose as a LOAEL.

The approach to scoring mammary gland development was not consistent across studies and little information was provided on the qualitative components of the scores. This makes comparisons across studies difficult. Statistical significance was attained at higher dose levels for the quantitative portion of the Macon et al. (2011) scoring protocol than for the qualitative component of the score. Tucker et al. (2015) found that CD-1 mice were considerably more sensitive to effects on mammary gland development (LOAEL 0.01 mg/kg/day) than C57BL/6 mice (NOAEL 0.1 mg/kg/day). Scoring was conducted using the Macon et al. (2011) approach.

White et al. (2011) used doses of 0 or 1 mg PFOA/kg/day for F0 dams throughout gestation with and without the addition of drinking water containing 5-ppb PFOA beginning on gestation day 7 and continuing the contaminated drinking water during the production of two more generations; no persistent significant differences were found in the body weights of the pups in the F1 and F2 generations for the pups receiving 1 mg/kg/day, indicating a poor correlation between mammary duct branching patterns and the ability to support pup growth during lactation. The 5-mg/kg/day dose did affect body weight. Albrecht et al. (2013) also found no
significant impacts on pup body weight in their one-generation assay at a dose of 3 mg/kg/day. Despite the diminished ductal network assessed in the qualitative mammary gland developmental score of the dams in White et al. (2011), milk production was sufficient to nourish growth in the exposed pups as reflected in the body weight measurements compared to controls at the 1-mg/kg/day dose. The MOA for PFOA-induced delayed mammary gland development is unknown and requires further investigation.

8.5 Alternative Exposure Scenarios

EPA is issuing a lifetime HA for PFOA of 0.07 µg/L to prevent a variety of adverse developmental effects to fetuses during pregnancy and to infants during breast feeding. Due to the potential increased susceptibility during this critical time period, EPA used drinking water intake and body weight parameters for lactating women to calculate the lifetime HA (see section 6.2). Specifically, EPA used the rate of 54 mL/kg-day representing the consumers only estimate of combined direct and indirect community water ingestion at the 90th percentile for lactating women (see Table 3-81 in USEPA [2011b]).

As a comparative analysis, EPA calculated a lifetime HA value for alternative exposure scenarios for the general population. Calculation of a lifetime HA value for the general population (adults ages 21 and older) is 0.1 µg/L, assuming a drinking water rate of 2.5 L/day and a mean body weight of 80 kg (see Tables 3-33 and 8-1 in USEPA[2011b]).

PFOA is extremely persistent in both the human body and the environment; thus, even a short-term exposure results in a body burden that persists for years and can increase if additional exposure occurs later. Human studies have shown that PFOA is transferred from mother to infant via cord blood and breast milk. The exposure scenario for the lactating woman is the most protective given her increased water intake rate to support milk production and thus is the basis for EPA’s recommended lifetime HA for PFOA of 0.07 µg/L. The lifetime HA for PFOA is also protective of adverse health effects in the adult general population (e.g., testicular and kidney cancer, liver damage, immune effects).

8.6 Relative Source Contribution Considerations

EPA used the Exposure Decision Tree methodology to derive the RSC for this HA (USEPA 2000). Findings from studies on populations in the United States, Canada, and Western Europe support the conclusion that diet is the major contributor to total PFOA exposure, typically with drinking water and/or dust as important additional exposure routes, especially for sensitive subpopulations. Estimates of relative exposure from different sources vary widely, as described below.

- Tittlemier et al. (2007) conducted a total diet study, focused on collection and analysis of different food items. They concluded that diet represented approximately 60% of exposure to total PFASs, with a negligible contribution from drinking water, based on samples collected from two cities in Canada.
- Lorber and Egeghy (2011) used models to estimate exposures for adults and 2-year-olds. The data and analysis identify dietary ingestion as the major contributor to adult intake of PFOA, and dust and diet for young children in different media. The authors estimated
PFOA exposure from drinking water at 17 ng/day or approximately 24% of total intake for both adults and children. As background concentrations of PFOA in water increase, drinking water represents a greater source of total dietary intake.

- Gebbink et al. (2015) estimated the relative contributions of the major exposure media to total direct and indirect PFOA exposures under assumptions of low (5th percentile), intermediate (median values), and high (95th percentile) exposures. The authors used a scenario-based risk assessment modeling approach with data collected in 2007 to estimate the relative contributions of diet, dust, water, and air to total exposures. Only data for samples collected in North America, Europe, Korea, and Japan were included in the evaluation. The authors point out that both the blood serum concentrations and the temporal trends of PFASs in the United States, Europe, and Japan are similar. The data for direct and indirect contributors to serum PFOA are presented graphically in the published paper. They are consistent with the following exposure patterns for the combination of direct and indirect (precursor) exposures in adults:
  - Low-exposure scenario: diet (~50%) > air (~25%) > dust (~15%) > water (~10%);
  - Intermediate-exposure scenario: diet (~45%) > dust (~35%) > water (~10%) ≈ air (~10%); and
  - High-exposure scenario: dust (~65%) > diet (~20%) > water (10%) > air (~5%).

As the environmental level increases, so does the contribution of precursors to total exposure, increasing from about 15% to 30% to 60% as the exposure increases from low to high.

The approaches and assumptions used in these studies vary widely; some uncertainties associated with these data include:

- Many of the data are obtained from review papers or individual studies conducted at single locations often in Europe and are not nationally representative.
- Concentrations range widely in exposure estimates.
- The ambient air and dust exposure estimates are limited, regional, and variable.
- Drinking water exposure varies among age groups and individuals.
- Because of recent reductions in use of PFOA and its precursors, it is difficult to assess current relative exposures to the general population.

Additionally, there is a lack of data on other routes of exposure:

- Estimates of dermal exposure to treated fabrics and inhalation exposure associated with contaminated water are not available.
- Drinking water exposure estimates apply only to direct ingestion of tap water and beverages or soups prepared locally. They do not generally include PFOA in water that becomes incorporated in solid foods during home preparation and cooking or that is present in commercial beverages.
- Transformation of PFOA precursors that decay or are metabolized to PFOA is a route that is rarely evaluated in dietary studies yet can contribute to total exposure. Air and dust can be vehicles for derivatives that metabolically degrade to PFOA.

Given these uncertainties, EPA used the Exposure Decision Tree methodology, described in section 6.1, to estimate an RSC of 20% for drinking water for the general population.
8.7  Sensitive Populations: Gender Differences

Some animal species have gender differences that affect toxicity of PFOA. Sexually mature female rats excreted almost all of a 10-mg/kg dose of PFOA within 48 hours compared to only 19% excreted by male rats. Male hamsters excrete PFOA faster than female hamsters, and female rabbits excrete PFOA slightly faster than male rabbits. Male and female mice excrete PFOA at approximately the same rate (Hundley et al. 2006). Studies of the transporters involved in the toxicokinetics of PFOA demonstrate that they are differentially affected by the presence of male and female sex hormones (Cheng et al. 2006; Kudo et al. 2002). As studied in rats (Kudo et al. 2002), the male sex hormones increased half-life (decreased excretion) of PFOA while the female hormones were associated with shorter half-lives (increased excretion). The gender differences in toxicokinetics in mice are not as pronounced as those in rats. Work by Cheng et al. (2006) and Cheng and Klaassen (2009) demonstrated that the hormones affected transporters in the liver and kidney, protecting the females and increasing the sensitivity for males. Results of the NHANES data on PFOA suggest that in humans, serum levels are lower in females (Calafat et al. 2007a, 2007b; Jain 2014); both menstruation and lactation are excretory routes in females and shorten the half-life of PFOA during associated life phases.

In studies where both male and female rats were used, the males were more sensitive to toxicity than the females (Butenhoff et al. 2004a). Mice displayed similar sensitivities following PFOA exposure (Kennedy 1987). In the monkey studies, the number of animals per gender per dose group was too small to reveal a difference related to gender.

Unfortunately, much work remains to be done to determine whether the gender difference seen in rats is relevant to humans. Similarities are possible because the long half-life in humans suggests that they might be more like the male rat than the female rat. The broad range of half-lives in human epidemiology studies suggests a variability in human transport capabilities resulting from the isomeric composition of the PFOA and genetic variations in transporter structures and consequently in function (Y. Zhang et al. 2013, 2014). Genetic variation in human transporters are identified in a review by Zaïr et al. (2008).

8.8  Sensitive Populations: Developmental Effects

PFOA-exposure during development in rats and mice resulted in increased resorptions (mouse), increased fetal skeletal variation (rats, mouse), decreased neonatal survival (rat, mouse), decreased postnatal body weight (mouse), delayed eye opening and body hair growth (rat, mouse), delayed vaginal opening (mouse), accelerated preputial separation (mouse), and delayed mammary gland development (mouse) (Butenhoff et al. 2004a; Lau et al. 2006; Macon et al. 2011; Tucker et al. 2015; White et al. 2007, 2009, 2011; Wolf et al. 2007). Some effects were seen as low-dose exposures such as the ossification delays and accelerated puberty in male mice exposed via their dams to a dose of 1 mg/kg/day during gestation (Lau et al. 2006), the mammary gland effects (0.01 mg/kg/day) (Macon et al. 2011), and the postnatal effects on body weight in pups exposed to PFOA during gestation and lactation to doses of 3 or 5 mg/kg/day (White et al. 2009; Wolf et al. 2007). Only the low birth weight receives support from the epidemiology studies. The other effects generally lack correlates among the effects evaluated by the studies.
In the Wolf et al. (2007) study, pup postnatal body weights were lower than controls for all exposure durations during the last 10 days of gestation evaluated. The authors found that the magnitude of the body weight effect was directly related to the days of exposure (i.e., 3, 5, 7, or 10); the longer the exposure, the greater the body weight deficit in the male and female pups during the PND 2–22 time period. In male but not female pups, the exposure duration deficits in body weight persisted up to PND 92. The difference in the male rat response over the PND 29–92 period likely reflects their longer half-life than females.

Both gestational and lactational exposures contribute to the impact of PFOA on body weight during early life as illustrated by cross-fostering control unexposed female pups with those dosed with PFOA. Three cross-fostering combinations were evaluated by White et al (2009): control pups nursed by exposed dams, exposed pups nursed by control dams, and exposed pups nursed by exposed dams. Two doses were evaluated: 3 and 5 mg/kg/day. The PND 1–10 body weight data were only provided for the 5-mg/kg/day dose. PFOA exposures significantly reduced pup body weights and increased liver weights. The body weight deficits compared to control were greatest for the gestation and lactation exposure combination and lowest for the lactation-only group.

Diet can influence the risk associated with PFOA exposures. Animal studies demonstrate an increased risk for liver steatosis in animals on a high-fat diet and possibly for insulin resistance (Hines et al. 2009; Quist et al. 2015; Tan et al. 2013). The epidemiology data are not supportive of a correlation with insulin resistance, but the observations of elevated serum triglycerides, especially among a highly exposed population, could be viewed as a risk factor for steatosis. Most of the epidemiology studies did not evaluate dietary factors as part of the study design for either birth weight or serum lipids (e.g., cholesterol, triglycerides, LDL).

9.0 ANALYTICAL METHODS

EPA developed a liquid chromatography/tandem mass spectrometry (LC/MS/MS) analytical method—Method 537—to monitor drinking water for 14 select perfluorinated alkyl acids that include PFOA (USEPA 2009b). Accuracy and precision data were generated for PFOA, PFOS, and the other 12 PFASs in reagent water, finished ground water, and finished surface water. This method identifies a single laboratory lowest concentration minimum reporting level or quantitation limit for PFOA at 5.1 ng/L (0.0051 µg/L) and for PFOS at 6.5 ng/L (0.0065 µg/L). The method-published detection limit for PFOA is 1.7 ng/L (0.0017 µg/L).

In this method, PFAS standards, extracts, and samples should not come into contact with any glass containers or pipettes because PFASs can potentially adsorb to the surface of the glassware. Polypropylene containers should be used instead. Also, these compounds can be found in commonly used laboratory supplies and equipment, such as PTFE products, liquid chromatograph solvent lines, methanol, aluminum foil, and solid phase extraction (SPE) sample transfer lines. These materials need to be routinely demonstrated to be free of interferences per the guidelines for laboratory reagent blanks described in the method. In summary, the method procedure involves passing a preserved 250-mL water sample (fortified with an extraction surrogate) through a SPE cartridge containing polystyrenedivinylbenzene (SDVB) to extract the method analytes and surrogates.
The compounds are eluted from the SPE with a small amount of methanol. The extract is concentrated to dryness with nitrogen in a heated water bath, and then adjusted to a 1-mL volume with 96%:4% (vol/vol) methanol:water after adding the internal standards. The extract is injected into a liquid chromatograph that is interfaced to an MS/MS. The analytes are separated and identified by comparing the acquired mass spectra and retention times to reference spectra and retention times for calibration standards acquired under identical LC/MS/MS conditions. The concentration of each analyte is determined by using the internal standard technique. Surrogate analytes are added to all field and quality control samples to monitor the extraction efficiency of the method analytes. *Method 537: Determination of Selected Perfluorinated Alkyl Acids in Drinking Water by Solid Phase Extraction and Liquid Chromatography/Tandem Mass Spectrometry (LC/MS/MS)* (USEPA 2009b) is available for download at [http://www.epa.gov/nerlcwww/ordmeth.htm](http://www.epa.gov/nerlcwww/ordmeth.htm).

### 10.0 TREATMENT TECHNOLOGIES

As mentioned above, PFOA is an organic compound in which the carbon-hydrogen bonds are replaced by carbon-fluorine bonds. This influences the chemical characteristics of both molecules and, therefore, will impact the effectiveness of any given drinking water treatment process. The characteristics of organic contaminants that treatment processes take advantage of include molecular size, solubility, ionic form, volatility, oxidizability, hydrolysis, photolysis, and biodegradability. Because fluorine is the most electronegative element, the carbon-fluorine bond will be one of the strongest bonds in nature, making it exceedingly resistant to biodegradation, hydrolysis, oxidation, and photolysis. Also, because PFOA is a dissolved contaminant that is resistant to oxidation to an insoluble form, treatment processes that are designed for particulate control such as conventional treatment will not be effective. This leaves adsorption, ion exchange resins, and high-pressure membranes as the technologies that can be effective. The following subsections discuss the effectiveness of commonly used drinking water technologies in rough order of applicability for PFOA and PFOS removal. Additional information can be found on EPA’s Drinking Water Treatability Database (USEPA 2015b) at [https://iaspub.epa.gov/tdb/pages/general/home.do](https://iaspub.epa.gov/tdb/pages/general/home.do).

To varying degrees of applicability, the technologies discussed below can be employed in centralized drinking water facilities or in a distributed fashion such as point-of-entry (POE) or point-of-use (POU) applications in buildings and homes. As they imply, POE systems treat the water as it enters the building or house, and POU systems treat the water where used, such as a kitchen or bathroom sink. Although the cost of treatment varies with scale, the following general discussion on the relative effectiveness of each technology applies regardless of scale. One reference below specifically addresses POU systems (MDH 2008).

**Activated Carbon Adsorption**

Activated carbon is applied in either powdered or granular form. Either can be effective; however, because PFOA and PFOS have moderate adsorbability, the specifics of the design are very important for achieving successful treatment.
Powdered Activated Carbon

Powdered activated carbon (PAC) is often applied prior to, or within a, conventional treatment train. The contaminant-loaded PAC is then removed along with the other particulates. Although some studies have shown limited PFOA and PFOS removal in plants using PAC (Quiñones and Snyder 2009), in general, PAC can be an effective treatment strategy for the removal of PFOA and PFOS given the correct choice of carbon type, high enough carbon doses, and adequate contact time (Dudley et al. 2015; Hansen et al. 2010).

Granular Activated Carbon

Granular activated carbon is applied as a filtration step either as a filter adsorber where a relatively short carbon cap is added to an existing sand filter, or as a post-filter adsorber where a deeper bed is employed as a stand-alone unit following a typical sand filter. Because PFOA and PFOS have moderate adsorbability, a post-filter adsorber with a deeper bed is considered a safer approach. In general, granular activated carbon treatment was found to be effective given the correct choice of carbon, adequate bed depth, moderate or low hydraulic loading rate, and frequent replacement or regeneration of the carbon (Appleman et al. 2013, 2014; MDH 2008; Shivakoti et al. 2010; Takagi et al. 2008).

Membrane Technologies

There are many types of membrane technologies. They can be broadly classified as either low-pressure or high-pressure systems. This distinction also corresponds to the general effectiveness of removing PFOA and PFOS with low-pressure membranes being ineffective, while high-pressure membranes are effective.

Low-pressure Membranes

Low-pressure systems incorporating cartridge, microfiltration, or ultrafiltration membranes are designed for particulate control. They have relatively large pore structures through which water and dissolved contaminants can easily flow, leaving behind larger particulate matter that includes turbidity and microbiological agents. Low-pressure membranes have been found to be ineffective for PFOA and PFOS control (McLaughlin et al. 2011; Thompson et al. 2011). This is consistent with other treatment processes (e.g., conventional treatment) that target particulate contaminants but not dissolved contaminants. However, as with conventional treatment, low-pressure membranes can be effective if they are used in conjunction with PAC. The PAC will adsorb the PFOA and PFOS, and the low-pressure membrane will remove the spent PAC. Care should be taken in the design of the system, including the choice of the PAC as mentioned above (Dudley et al. 2015).

High-pressure Membranes

High-pressure systems have a much tighter pore structure, relying on water diffusing through the membrane material. High-pressure systems such as nanofiltration and reverse osmosis can reject not only particulates, but also dissolved constituents such as organic contaminants and salts. Reverse-osmosis membranes are the tightest of the high-pressure systems, having the ability to reject monovalent salts such as sodium chloride (e.g., sea water desalination). High-pressure membrane systems have been shown to be very effective for PFOA and PFOS
Ion Exchange Resin Treatment

There are two broad categories of ion exchange resins: cationic and anionic. Cationic exchange resins are effective for removing positively charged contaminants. Anion exchange resins are effective for negatively charged contaminants. Because PFOA and PFOS are negatively charged in drinking waters, cation-exchange resins will not be effective, and therefore, have not been studied. There have been studies that have evaluated different anion exchange resins (macroporous styrenedivinylbenzene, gel-type polystyrene divinylbenzene, and polyacrylic quaternary amine resins). Generally, anion exchange resins have been found to be effective for PFOA and PFOS removal (Appleman et al. 2014; Carter and Farrell 2010; Chularueangaksorn et al. 2013; Dudley et al. 2015), although the design of the system including regeneration effectiveness is important. Special consideration should be given to dealing with the regenerate brine waste, and if frequent regenerations are needed, to the amount of operator effort and expertise required.

Oxidation / Disinfection

Oxidation/disinfection processes can transform certain contaminants into different molecules, which ideally have less toxicity. It also can transform certain dissolved constituents into a higher oxidation state that might be less soluble (e.g., iron, manganese). The less soluble form can then be precipitated and removed in the floc or on a media filter of a conventional treatment system. Due to the strength of the carbon-fluorine bond, all drinking water oxidants or disinfectants have been shown to be ineffective in reacting PFOA or PFOS. This has been shown numerous times for common oxidative/disinfection agents such as packed tower aeration, chlorination, chloramination, ozonation, potassium permanganate, and ultraviolet (UV) treatment (Appleman et al. 2014; Hori et al. 2004; Liu et al. 2012; McLaughlin et al. 2011; Quiñones and Snyder 2009; Schröder and Meesters 2005; Shivakoti et al. 2010; Thompson et al. 2011). It also is true for advanced oxidation processes (AOPs) that use the nonselective hydroxyl radical as an oxidative agent. There are many ways of producing hydroxyl radicals, usually combining technologies such as hydrogen peroxide plus iron (Fenton’s reagent), ozone plus peroxide, UV plus titanium dioxide, UV plus ozone, and UV plus peroxide. All of these combinations have been shown to be ineffective for PFOA and PFOS control at reasonable contact times (Benotti et al. 2009; Hori et al. 2004; Schröder and Meesters 2005; Tellez 2014).

Biological Treatment

Similar to the discussion on oxidation processes, because of the strength of the carbon-fluorine bond, it is expected that both aerobic and anaerobic biological treatment processes (e.g., biofiltration, bioreactors) are expected to be ineffective for PFOA and PFOS removal. A number of researchers have found this to be the case (Kwon et al. 2014; Saez et al. 2008; Thompson et al. 2011). Some results have shown that specific microbes could have the ability to break the carbon-to-carbon bonds in PFOS, albeit slowly; however, this cannot be engineered into a consistent and robust treatment process (Kwon et al. 2014).
Conventional Treatment

Conventional treatment is commonly defined as a series of successive steps: rapid mix, coagulation, flocculation, sedimentation, and filtration. Certain variations exist, such as direct filtration, which does not employ a sedimentation step. Regardless of the configuration, conventional treatment is designed to remove particulates (e.g., turbidity and microbiological agents). Dissolved contaminants, however, will not be removed by conventional treatment. The exception is when the contaminants are first oxidized to an insoluble form (e.g., iron, manganese), or if they are exceedingly hydrophobic as evidenced by an extremely low solubility. Therefore, because of the resistance of PFOA and PFOS to oxidation to an insoluble form and their moderately high solubility, conventional treatment is not expected to be effective in their removal, even in enhanced coagulation conditions. Numerous studies have confirmed this statement (Appleman et al. 2014; Loos et al. 2007; Quiñones and Snyder 2009; Shivakoti et al. 2010; Skutlarek et al. 2006; Tabe et al. 2010; Takagi et al. 2008; Thompson et al. 2011; Xiao et al. 2013).

Similar to low-pressure membranes, conventional treatment can be effective if it is used in conjunction with PAC (see above). The PAC will adsorb the PFOA and PFOS, and the conventional treatment system will remove the spent PAC in the sedimentation and filtration steps. Care should be taken in the design of the system, including the choice of the PAC (Dudley et al. 2015).
REFERENCES


EFSA (European Food Safety Authority). 2008. Opinion of the scientific panel on contaminants in the food chain on perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA) and their salts. EFSA Journal 653:1–131.


Innes, K.E., J.H. Wimsatt, S. Frisbee, and A.M. Ducatman. 2014. Inverse association of colorectal cancer prevalence to serum levels of perfluorooctane sulfonate (PFOS) and perfluorooctanoate (PFOA) in a large Appalachian population. *BMC Cancer* 14:45.


Loos, R., J. Woollgast, T. Huber, and G. Hanke. 2007. Polar herbicides, pharmaceutical products, perfluorooctanesulfonate (PFOS), perfluorooctanoate (PFOA), and nonylphenol and its carboxylates and ethoxylates in surface and tap waters around Lake Maggiore in Northern Italy. *Analytical and Bioanalytical Chemistry* 387:1469.


Drinking Water Health Advisory for Perfluorooctanoic Acid (PFOA) – May 2016


Multistage Model for Leydig Cell Tumors

The form of the probability function is:
\[ P[\text{response}] = \text{background} + (1 - \text{background}) \times (1 - \exp(-\beta_1 \times \text{dose}^1 - \beta_2 \times \text{dose}^2)) \]

The parameter betas are restricted to be positive

--

Default Initial Parameter Values

\begin{align*}
\text{Background} &= 0.0132945 \\
\beta_1 &= 0.0097738 \\
\beta_2 &= 0
\end{align*}

Asymptotic Correlation Matrix of Parameter Estimates

\[ (*** \text{ The model parameter(s)} - \beta_2 \text{ have been estimated at a boundary point, or have been specified by the user, and do not appear in the correlation matrix } ) \]

\[ \begin{array}{cc}
\text{Background} & \beta_1 \\
\text{Background} & 1 & -0.64 \\
\beta_1 & -0.64 & 1 \\
\end{array} \]
Parameter Estimates

<table>
<thead>
<tr>
<th>Variable</th>
<th>Estimate</th>
<th>Std. Err.</th>
<th>95.0% Wald Confidence Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Background</td>
<td>0.00409839</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>Beta(1)</td>
<td>0.0116288</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>Beta(2)</td>
<td>0</td>
<td>*</td>
<td>*</td>
</tr>
</tbody>
</table>

* - Indicates that this value is not calculated.

Analysis of Deviance Table

<table>
<thead>
<tr>
<th>Model</th>
<th>Log(likelihood)</th>
<th># Param's</th>
<th>Deviance</th>
<th>Test d.f.</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full model</td>
<td>-28.6454</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fitted model</td>
<td>-29.3468</td>
<td>2</td>
<td>1.40286</td>
<td>1</td>
<td>0.2362</td>
</tr>
<tr>
<td>Reduced model</td>
<td>-34.0451</td>
<td>1</td>
<td>10.7995</td>
<td>2</td>
<td>0.004518</td>
</tr>
</tbody>
</table>

AIC: 62.6936

Goodness of Fit

<table>
<thead>
<tr>
<th>Dose</th>
<th>Est. Prob.</th>
<th>Expected</th>
<th>Observed</th>
<th>Size</th>
<th>Scaled Residual</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.0000</td>
<td>0.0041</td>
<td>0.205</td>
<td>0.000</td>
<td>50</td>
<td>-0.454</td>
</tr>
<tr>
<td>1.3000</td>
<td>0.0190</td>
<td>0.952</td>
<td>2.000</td>
<td>50</td>
<td>1.084</td>
</tr>
<tr>
<td>14.2000</td>
<td>0.1557</td>
<td>7.784</td>
<td>7.000</td>
<td>50</td>
<td>-0.306</td>
</tr>
</tbody>
</table>

Chi^2 = 1.48 d.f. = 1 P-value = 0.2245

Benchmark Dose Computation

<table>
<thead>
<tr>
<th>Specified effect</th>
<th>0.04</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risk Type</td>
<td>Extra risk</td>
</tr>
<tr>
<td>Confidence level</td>
<td>0.95</td>
</tr>
<tr>
<td>BMD</td>
<td>3.51044</td>
</tr>
<tr>
<td>BMDL</td>
<td>1.99346</td>
</tr>
<tr>
<td>BMDU</td>
<td>10.7788</td>
</tr>
</tbody>
</table>

Taken together, (1.99346, 10.7788) is a 90% two-sided confidence interval for the BMD

Multistage Cancer Slope Factor = 0.0200656
BMDS_Model_Run
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
The form of the probability function is:

\[ P[\text{response}] = \text{background} + (1-\text{background}) \times (1-\text{EXP}(-\beta_1 \times \text{dose}^1)) \]

The parameter betas are restricted to be positive

Dependent variable = Col2
Independent variable = Col1

Total number of observations = 3
Total number of records with missing values = 0
Total number of parameters in model = 2
Total number of specified parameters = 0
Degree of polynomial = 1
Maximum number of iterations = 250
Relative Function Convergence has been set to: 1e-008
Parameter Convergence has been set to: 1e-008

Default Initial Parameter Values

Background = 0.0132945
Beta(1) = 0.0097738

Asymptotic Correlation Matrix of Parameter Estimates

<table>
<thead>
<tr>
<th></th>
<th>Background</th>
<th>Beta(1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Background</td>
<td>1</td>
<td>-0.64</td>
</tr>
<tr>
<td>Beta(1)</td>
<td>-0.64</td>
<td>1</td>
</tr>
</tbody>
</table>

Parameter Estimates

<table>
<thead>
<tr>
<th>Variable</th>
<th>Estimate</th>
<th>Std. Err.</th>
<th>95.0% Wald Confidence Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Background</td>
<td>0.00409839</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>Beta(1)</td>
<td>0.0116288</td>
<td>*</td>
<td>*</td>
</tr>
</tbody>
</table>

* - Indicates that this value is not calculated.

Analysis of Deviance Table

<table>
<thead>
<tr>
<th>Model</th>
<th>Log(likelihood)</th>
<th># Param's</th>
<th>Deviance</th>
<th>Test d.f.</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full model</td>
<td>-28.6454</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fitted model</td>
<td>-29.3468</td>
<td>2</td>
<td>1.40286</td>
<td>1</td>
<td>0.2362</td>
</tr>
<tr>
<td>Reduced model</td>
<td>-34.0451</td>
<td>1</td>
<td>10.7995</td>
<td>2</td>
<td>0.004518</td>
</tr>
</tbody>
</table>

AIC: 62.6936

Goodness of Fit

<table>
<thead>
<tr>
<th>Dose</th>
<th>Est. Prob.</th>
<th>Expected</th>
<th>Observed</th>
<th>Size</th>
<th>Scaled Residual</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.0000</td>
<td>0.0041</td>
<td>0.205</td>
<td>0.000</td>
<td>50</td>
<td>-0.454</td>
</tr>
<tr>
<td>1.3000</td>
<td>0.0190</td>
<td>0.952</td>
<td>2.000</td>
<td>50</td>
<td>1.084</td>
</tr>
<tr>
<td>14.2000</td>
<td>0.1557</td>
<td>7.784</td>
<td>7.000</td>
<td>50</td>
<td>-0.306</td>
</tr>
</tbody>
</table>

Chi^2 = 1.48  d.f. = 1  P-value = 0.2245
Benchmark Dose Computation

    Specified effect = 0.04
    Risk Type = Extra risk
    Confidence level = 0.95
    BMD = 3.51044
    BMDL = 1.99346
    BMDU = 8.7003

Taken together, (1.99346, 8.7003) is a 90% two-sided confidence interval for the BMD

Multistage Cancer Slope Factor = 0.0200657